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Substantial evidence indicates that plasma lipoprotein-lipid levels are related to 
cardiovascular disease, are highly variable among individuals, and have a strong genetic 
component.  They are also modifiable with exercise training, and these responses are
heritable.  A small body of literature suggests an association between the interleukin-6 
(IL6) –174G/C gene polymorphism and plasma lipoprotein-lipid levels such that the G 
allele may be associated with a more pro-atherogenic lipid profile than the C allele.  We 
hypothesized that the IL6 –174G/C gene polymorphism would be associated with 
variation in plasma lipoprotein-lipid profiles at baseline and with their response to 
exercise training.  
Sixty-five sedentary, healthy 50- to 75-year-old Caucasians were studied before 
and after 24 weeks of aerobic exercise training.  Significant differences existed among 
genotype groups for change with exercise training in high-density lipoprotein (HDL)-C, 
HDL3-C, HDL5NMR-C, HDL4NMR-C, integrated HDL4,5NMR -C, and HDLsize.  For HDL-C, 
the CC group increased significantly more than both the GG (7.0 ± 1.3 v. 1.0 ± 1.1 
mg/dL, p=0.001) and the GC group (3.3 ± 0.9 mg/dL, p=0.02).  For HDL3-C, the CC 
group increased significantly more than both the GG (6.1 ± 1.0 v. 0.9 ± 0.9, mg/dL 
p<0.001) and the GC group (2.5 ± 0.7 mg/dL, p=0.006).  For HDL5NMR-C, the GC group 
increased significantly less than both the CC and GG groups (0.0 ± 0.7 v. 3.4 ± 1.0 
mg/dL, p=0.02 and 1.4 ± 0.8 mg/dL, p=0.04).  For HDL4NMR-C, the GG group changed 
significantly differently from both the GC and CC groups with the GG group decreasing 
and the GC and CC groups increasing HDL4NMR-C (-0.4 ± 1.1 v. 3.1 ± 0.9 mg/dL, p=0.02 
and v. 3.2 ± 1.3 mg/dL, p=0.05, respectively).   For integrated HDL4,5-C, the CC group 
increased significantly more than the GG group (6.5 ± 1.6 mg/dL v. 1.0 ± 1.3 mg/dL, 
p=0.01).  For HDLsize, the CC group increased significantly more than both the GG (0.3 ±
0.1 v. 0.1 ± 0.1 nm, p=0.02) and the GC groups (0.0 ± 0.0 nm, p=0.007).  These findings 
suggest that the IL6-174G/C polymorphism influences HDL-C and HDL-C subfraction 
changes with exercise training.
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Currently the leading cause of morbidity and mortality in the developed 
world, cardiovascular (CV) disease will soon be the most critical health problem 
across the globe.137,190  For over 30 years, plasma lipoprotein-lipids have been 
identified as major physiological contributors to the pathophysiology of 
atherosclerotic vascular disease, and they are highlighted as a major risk factor 
category for its development.190,196,201-203  However, recent evidence suggests that 
inflammation may be the underlying mechanism that regulates the atherosclerotic 
process and potentially explains how the various CV disease risk factors influence 
each other and the development of CV disease.29,47,49,131,133,144,175,176,179,199,252  This 
line of research suggests that various conditions and factors can result in the 
establishment of a chronic low grade inflammatory state, marked by elevated 
inflammatory activity that has a beneficial role in the innate immune response but, if 
present for prolonged periods of time, can become physiologically 
detrimental.80,105,106,252  As the major mediator of this inflammatory activity, the 
inflammatory cytokine interleukin-6 (IL-6) may serve as the molecular link between 
metabolic, endothelial, and coagulatory CV disease risk factors, including alterations 
in lipid metabolism, dyslipidemia, and proatherogenic changes in lipoproteins, and 
the pathogenesis of atherosclerosis.80,105,106,133,135,252
IL-6 is a multifunctional cytokine secreted by a variety of cell types including 
lymphocytes, macrophages, monocytes, endothelial cells, adipocytes, and skeletal 
muscle.80,82,162,239  Possessing autocrine, paracrine, and endocrine functions, it acts as 
a major regulator of the hepatic acute phase response and plays a role in coagulatory 
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status, endothelial function, energy regulation, and lipid 
metabolism.42,56,136,161,162,170,224,238  These biological activities result in increased 
levels of circulating acute phase proteins such as C-reactive protein (CRP) and serum 
amyloid A (SAA), soluble adhesion molecules, plasminogen-activator-1 (PAI-1), and 
fibrinogen, decreased nitric oxide secretion, increased basal glucose uptake, 
decreased insulin sensitivity, increased TG and non- esterified FFA levels, and 
decreased HDL-C levels.136,162,239,252,253  IL-6 also acts to stimulate the hypothalamic-
pituatary-adrenal axis, induce the secretion of vasopressin and growth hormone, and 
suppress the thyroid axis.162,242,252  However, due to such initiation factors as chronic 
low-grade infection, obesity, environmental or emotional stress, or genetic 
programming, IL-6 can become chronically elevated, resulting in the prolonged 
activation of these biological activities.105,252  This dysregulation in IL-6 levels, 
irrespective of cause or magnitude, could then turn the initially beneficial responses 
into deleterious conditions.44,47-50,206,243,252
Genetic factors affecting IL6 gene transcription and expression are one 
potential influence on IL-6 production.53,252  Several potentially functional promoter 
polymorphisms have been identified in the IL6 gene 5’ flanking region that may 
influence IL6 gene transcription and thus IL-6 production, including the –597G/A, -
572 G/C, -373AnTn, and –174G/C promoter polymorphisms.
23,51-53,57,98,146,225,232,242
Whether these single nucleotide polymorphisms (SNPs) alone or in combinations are 
responsible for alterations in IL6 gene function is unclear.23,51-53,57,98,146,225,232,242
However, previous work supports strong linkage disequilibrium among these 
polymorphisms, gives estimates for 94% of the haplotype combinations at these loci, 
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and supports the use of the –174G/C promoter polymorphism as a marker for the 
most frequent of those haplotypes.23,51-53,57,98,146,225,232,242  Additionally, research has 
shown associations between the –174G/C polymorphism, IL-6 levels, and various 
health related phenotypes, including bone mineral density, insulin sensitivity, and 
plasma lipoprotein lipid levels.44,46,49,50,93,127,138,226,242,243  For example, Fernandez-
Real et al.46 showed an association between IL-6 levels and dyslipidemia in which the 
–174 G allele showed a trend toward higher IL-6 levels and was associated with 
increased triglycerides (TG), very low-density lipoprotein triglycerides (VLDL-TG), 
and apolipoprotein B (apo B) and decreased high-density lipoprotein (HDL)2-C.  
Stouthard et al.226 found an associated between IL-6 and plasma free fatty acids.  
Epidemiological studies have also shown associations between elevated IL-6 levels 
and lipid abnormalities in which IL-6 was associated with increased TG in men with 
CV disease risk factors and with high TG and low HDL-C in healthy 100–106 year 
olds.9,133  Additionally, since inflammation is known to induce pro-atherogenic 
changes in lipoproteins and lipid metabolism and IL-6 is the primary mediator of the 
inflammatory response, it is biologically plausible that genetic variation in IL6, 
resulting in dysregulation of IL-6 levels, may be linked to alterations in lipid 
metabolism.68,86,105,106  Thus, the literature supports further investigation of the IL6 -
174G/C gene polymorphism in regard to IL-6 and various health phenotypes, 
including lipid metabolism and plasma lipoprotein-lipids. 
In addition to genetic variation, IL6 transcription rates, mRNA, and IL-6 
release are influenced by acute exercise.40-43,84,88,89,97,103,104,151,153,154,167-172,193,218,219,221-
224,238  The effect of exercise on the changes in IL6 gene expression and IL-6 release 
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are influenced by the mode, intensity, and duration of the exercise.42,154,172  For 
example, IL-6 levels have been shown to increase 100-fold following a marathon and 
to be augmented in states of low muscular glycogen.103,104,152  The primary source of 
the increase in IL-6 with exercise is the contracting skeletal muscle with the release 
stimulated by the muscle contraction itself, low intramuscular glycogen levels, or 
changes in energy turnover.104,168,171,172  Other organs, including adipose tissue, also 
release IL-6 during exercise.129,218  Thus, acting as an energy sensor and signaling 
molecule between the contracting muscle and other organs, the IL-6 protein appears 
to play a role in energy regulation during exercise as it functions to maintain glucose 
availability and mediate the mobilization of free fatty acids.129,170-172,218,224  In terms 
of exercise training, little data exists on the IL-6 response.  However, some evidence 
suggests that endurance exercise training may attenuate the IL- 6 response to exercise 
in CHF patients and healthy adults.3,13,59,177,235  In terms of the interactive effects of 
endurance exercise training and IL6 genotype on IL-6 levels and subsequently on 
plasma lipoprotein-lipids, we know of no investigations that have looked at that 
gene*environment interaction. 
In contrast to IL-6 response, endurance exercise training has been shown to 
produce favorable modifications in plasma lipoprotein-lipid levels.1,35,64,109,115-
117,214,233  Additionally, studies show that both baseline plasma lipoprotein lipid levels 
and their response to exercise training are influenced by genetic variation at specific 
lipid metabolism related gene loci.70,73,74,190,249  For example, in a meta-analysis of 52 
exercise training studies involving training protocols of > 12 weeks, Leon et al.116,117
found an average increase of 4.6% in HDL-C, an average reduction of 3.7% in TG, 
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and an average reduction of 5.0% in low-density lipoprotein (LDL)-C.  Similarly, 
Kraus et al.109 recently found that a relatively high amount of regular exercise 
significantly improved overall lipoprotein profiles, including an increase in total HDL 
concentration, large HDL particle concentration, and average size of HDL particles, 
even without clinically significant weight loss.  Halverstadt et al.74 found that genetic 
variation at a specific locus on the lipid metabolism related endothelial lipase gene 
was associated with inter-individual variability in HDL- C and its subfractions and 
their responses to exercise training.  Thus, combined with heritability estimates of 
0.64 for total cholesterol (TC), 0.67 for LDL-C, 0.42 for HDL-C levels, and .25 to .38 
for the general lipid response to exercise training, these studies support the role of 
exercise training in improving plasma lipoprotein lipid profiles and demonstrate that 
the variability in lipid levels and response to training is partially accounted for by a 
genetic component.75,79,91,174,181
With IL-6 having a very short biphasic half-life (initial 3 minute and then 
second 55 minute clearance), marked diurnal variability (low in the morning and high 
at bedtime), and large within and between individual variation (30% and 44%, 
respectively), accurate and consistent measurement is difficult.12,26,30,33,132,166,215,216
However, C-reactive protein (CRP) has been identified in the literature as a surrogate 
measure for plasma IL-6 levels as it is more stable (long-term stability in storage and 
half-life of 15 to 19 hours), lacks diurnal variability, is reproducible, and is regulated 
by IL-6.12,26,30,33,132,166,215,216  Additionally, while inconclusive as to which allele is 
associated with higher levels of CRP, evidence does suggest an association of the IL6 
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–174G/C polymorphism with CRP levels.51,107,241  Consequently, CRP levels can be 
used as a surrogate marker for plasma IL-6 levels.  
Thus, with research demonstrating the potential impact of genetic variation 
and the interaction of genetic variation with exercise training on IL-6 and plasma-
lipoprotein lipid levels, we hypothesized that the IL6 –174G/C gene polymorphism 
would be associated with variation in plasma lipoprotein-lipid profiles and their 
response to exercise training.  
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PURPOSE OF THE STUDY
The purpose of this investigation was to determine if the IL6 
–174G/C gene polymorphism was associated with plasma lipoprotein lipids and their 
subfractions at baseline and with their responses to exercise training.  
Hypotheses
1. IL6 genotype will influence plasma lipoprotein lipid levels such that 
carriers of the G allele will demonstrate a more pro-atherogenic baseline 
lipid profile (higher TC, TG, LDL-C, VLDL-TG, HDL2NMR-C and 
integrated HDL1,2NMR-C and lower HDL5NMR-C, HDL4NMR-C, HDL3NMR-C 
and integrated HDL3,4,5NMR-C and HDL4,5NMR-C) and will have higher 
baseline levels of CRP versus non-carriers of the G allele.
2. Carriers of the IL6 -174G allele will demonstrate less favorable changes in 
lipid profiles (less reduction or no change in TC, TG, LDL-C, VLDL-TG, 
HDL2NMR-C and integrated HDL1,2NMR-C and less of an increase or no 
change in HDL5NMR-C, HDL4NMR-C, HDL3NMR-C and integrated 
HDL3,4,5NMR-C and HDL4,5NMR-C) with exercise training as compared to 




Sixty-five healthy sedentary men and women were recruited for this study 
from the College Park, MD and Washington, D.C. metropolitan area.  Subjects 
underwent a telephone screening to determine their eligibility and interest.  The 
University of Maryland College Park Institutional Review Board approved the study, 
and written informed consent was obtained on all subjects.  All procedures were 
followed in accordance with institutional guidelines.  Eligibility for the study required 
subjects to be healthy, sedentary (regular aerobic exercise <2 times/wk and <20 
min/session, sedentary occupation), 50-75 years old, not on lipid- or glucose-lowering 
medications, normotensive or hypertension controlled (BP<160/99mmHg) with 
medications not affecting lipid metabolism (no thiazides, α- or β-blockers, etc), non-
diabetic, non-smoking, no history of CV disease, body mass index (BMI) < 37 kg/m2, 
and not have any other medical conditions that would preclude vigorous exercise.  All 
female participants were required to be > two years past menopause and agree to 
maintain their hormone replacement therapy (HRT) status (on or not on HRT) 
constant for the duration of the study.  
Screening
Screening Visit 1:  Medical histories were reviewed and BMI confirmed to be 
< 37 kg/m2.  A fasted blood sample was drawn for genotyping and plasma 
lipoprotein-lipid profile analysis.  Subjects had to have ≥ one National Cholesterol 
Education Program lipid abnormality (cholesterol > 200 mg/dL, HDL-C < 40 mg/dL, 
TG > 200 mg/dL); total cholesterol and low density lipoprotein cholesterol (LDL-C) 
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must have been < 90th and HDL-C > 20th percentile for their age and gender to 
exclude familial hypercholesterolemia.  Subjects had DNA isolated from peripheral 
monocytes134 and the DNA typed at the IL6 –174G/C locus (see Genotyping).  
Screening Visit 2:  Each subject had fasting blood samples drawn and 
underwent a two-hour 75-g oral glucose tolerance test to assess diabetes status.2  For 
study inclusion, subjects had to have fasting glucose levels < 126 mg/dL and 2-hour 
glucose levels < 200 mg/dL.  
Screening Visit 3:  Subjects qualified to this point underwent a physical and 
cardiovascular (CV) examination by a physician to detect CV, pulmonary, or other 
chronic diseases that would preclude exercise testing or training.6  They underwent a 
Bruce maximal treadmill exercise test to ensure they had no evidence of overt CV 
disease.22  Blood pressure, heart rate, and ECG were recorded before the test, at the 
end of every exercise stage, and every other minute for 6 minutes after exercise. The 
test was terminated when the subject could no longer continue or CV signs or 
symptoms occurred.6  Subjects had to have <2 mV ST-segment depression and no CV 
signs or symptoms during this test to be included in the study.6
Dietary Stabilization
All subjects underwent six weeks of dietary instruction (twice a week, one 
hour per session, for a total of 12 hours) with a registered dietician on the American 
Heart Association Step 1 diet.111  Subjects were required to follow this prescribed diet 
and be weight stable for > 3 weeks prior to undergoing baseline testing.  
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Baseline Testing
To analyze conventional plasma lipoprotein lipid levels, subjects had fasted 
samples drawn on two separate occasions, with the values averaged.  If these 
measures differed by > 10%, a third separate measurement was included in the 
average.  Plasma TG and cholesterol levels were analyzed in a Centers for Disease 
Control (CDC) certified lab using a CDC standardized Hitachi 717 autoanalyzer.4,211
HDL-C was measured after precipitation with dextran sulfate245, and LDL-C was 
calculated using the Friedewald equation.55  HDL2-C and HDL3-C were separated 
using a second high-molecular weight dextran sulfate precipitation with HDL3-C 
measured and HDL2-C calculated.
58
Nuclear magnetic resonance (NMR) techniques (LipoScience, Raleigh, NC) 
also were used to determine plasma lipoprotein lipids, using techniques previously 
standardized and validated against conventional methods of separation and 
analysis.159,190,192  NMR measures were made on a single blood sample that was 
frozen at –80° C.  Baseline and final test samples were analyzed at the same time.  
Rough equivalence of NMR and conventional HDL-C, LDL-C, and VLDL TG 
measures are as follows:  HDL1NMR-C ~ HDL3c-C; HDL2NMR-C ~ HDL3b-C; 
HDL3NMR-C ~ HDL3a-C; HDL4NMR-C ~ HDL2a-C; and HDL5NMR-C ~ HDL2b-C; 
LDL3NMR-C ~ LDLI, LDLIIa, and LDLIIb; LDL2NMR-C ~ LDLIIIa and LDLIIIb; 
LDL1NMR-C ~ LDLIVa and LDLIVb;  V5,V6 ~ large VLDL; V3, V4 ~ intermediate 
VLDL; and V1, V2 ~ small VLDL.
95,155-158,247  Coefficients of variation for standard 
lipid panel variables are < 3%, for VLDL, LDL, and HDL particle concentrations are 
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≤ 4%, and for individual subclasses contributing to total VLDL, LDL, and HDL are <
10%.95,155-158,247
Similar to lipid analysis, the CRP blood sampling required subjects to have 
had no alcohol for the previous 24 hours, no exercise for 24 – 36 hours, and no 
infections the previous week.  CRP was measured by enzyme-linked immunosorbent 
assay system (CRP measured at minimum detectable level of 0.35 ng/ml and inter-
assay coefficient of variation of 3-7%)(Alpha Diagnostic International, San Antonio, 
TX).  Blood samples were drawn, processed, and frozen at -80° C until assayed.  
Baseline and final samples were analyzed in the same assay run in order to prevent 
any inter-assay variation.  
Body composition was analyzed using dual-energy x-ray absorptiometry 
(DPX-L; Lunar Corp, Madison, WI).142  All subjects underwent a second maximal 
treadmill exercise test to assess VO2max as an index of CV fitness.
31  This test started 
at 70% of the peak heart rate achieved on the subject’s screening exercise test and 
treadmill grade was increased by 2% every 2 minutes.31  Blood pressure, heart rate, 
and ECG was monitored and the test terminated when the subject could no longer 
continue.  VO2 was measured continuously and directly using a customized metabolic 
system (Marquette Respiratory Mass Spectrometer, Rayfield Mixing Chamber, VMM 
Ventilatory Turbine) throughout the test and standard criteria were used to determine 
if a true VO2max had been achieved (no further increase in oxygen uptake with 
increased work rate (<150 ml/min), exceeding age-predicted maximal heart rate, or 
achieving a respiratory exchange ratio of greater than 1.15).6,208  VO2max was 
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measured to derive valid exercise prescriptions for the exercise training intervention 
and to quantify generalized CV training adaptations.  
Genotyping
IL6 –174G/C Promoter Polymorphism
High molecular weight DNA was isolated from peripheral monocytes 134 and 
genotyped for the –174 G to C promoter polymorphism of the IL6 gene (genotype 
groups:  G/G, G/C, or C/C) using fluorescence polarization (FP).204
Haplotype Information
Several polymorphisms have been identified in the 5’ flanking region of the 
IL6 gene that have been shown to be in at least partial linkage disequilibrium and to 
affect IL6 gene transcription and IL-6 protein production.23,51-53,57,98,146,225,232,242
These polymorphisms have been studied in relation to CVD and include the –
597G/A, -572 G/C, -373AnTn, and –174G/C promoter polymorphisms.
23,51-
53,57,98,146,225,232,242 Of these, the associations among the three biallelic polymorphisms 
have been most studied (–597G/A, -572 G/C, and –174G/C) with the –373 repeat 
polymorphism being less studied.23,51-53,57,98,146,225,232,242 Based on previous work, 
estimates of the frequency of the most common haplotype groups are as follows57,232:
Haplotype:  -597  -572  -174 GGG   AGC  GCG   GGC  AGG
Frequency (%) 54    40   5    0.6    0.3
Thus, knowing the –174G/C genotype allows for the estimation of 94% of the 
haplotype combinations for these three loci (GGG 54%; AGC 40%).  With only 65 
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subjects, typing of additional loci would only identify 4 additional subjects beyond 
the 61 identified by the –174G/C site.  
Additionally, these three biallelic loci have been shown to be in very strong 
linkage disequilibrium (LD) with each other (-597 and –572: D = -1; -174 and –597: 
D = +0.99; -174 and –572: D = -1.00; p<0.001).57  This strong LD further supports 
the use of the –174 loci as a marker for the most frequent haplotypes in which the 
typing of the additional SNPs would provide no additional information beyond that 
provided by the –174 locus.
The estimated haplotype frequencies for all four of the polymorphisms are as 
follows 232 :
Haplotype Frequency at Sites  -597, -572, -373AnTn, -174G/C:
AG8/12C (36%) GG10/11G (24%) GG9/11G(18%) GG10/10G(12%)
GC10/10G(6%) AG8/12G(1%) GG10/11G(1%) GG9/11C(1%)
The –373 AnTn run polymorphism has been shown to be in strong linkage 
disequilibrium with the –174G/C polymorphism 236 and associated with the biallelic 
haplotypes as follows:  the A8T12 polymorphism with the AGC haplotype, the 
A10T10 with the GCG haplotype, and the A9T11 with the GGC haplotype.23,53,232
However, since the effect of the –373 AnTn polymorphism on IL6 gene expression 
and transcription appears to be cell type specific, its influence is not yet completely 
understood, and all experiments have been conducted in vitro, no conclusions 
regarding its influence on human IL6 gene expression can be drawn from the 
literature and suggest that genotyping this site would provide no additional 
information to this study.23,53,232
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The present investigation will study only the –174G/C promoter 
polymorphism based on 1) previous work supporting the allelic association among 
the 5’ flanking region polymorphisms and providing estimates for 94% of the 
haplotypes at the –597G/A, -572G/C, and –174G/C loci, 2) results suggesting the 
–174G/C polymorphism as a marker for the most frequent of these haplotypes, and 3) 
evidence showing associations between the –174G/C polymorphism and specific 
health phenotypes.44,46,50-53,57,138,146,232,236,243  The genotyping and analysis of the 
additional SNPs would provide no additional information above that found from 
analyzing the –174 G/C site alone, particularly in light of this study having such a 
modest sample size.51,52,57,57,232
Exercise Training
Subjects underwent 24 weeks of supervised endurance exercise training 
consisting of 3 sessions/wk.  Heart rate monitors were used to assess training intensity 
and ensure that subjects trained at a heart rate corresponding to the appropriate 
intensity (% of VO2max).  Training began with 20 minutes at 50% VO2max and 
progressed to 70% VO2max for 40 minutes where it remained for the final 14 weeks.  
Subjects added a weekend lower intensity 45-60 minute exercise session during 
weeks 12-24.  Inclusion in the final analyses required subjects to have completed ≥
75% of training sessions.  To ensure dietary compliance, subjects completed diet 
records periodically throughout the exercise training.  
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Final Testing
After completing exercise training, all subjects completed the same tests as at 
baseline.  All blood samples were drawn 24-36 hours after a usual exercise training 
session.
Statistical Procedures
Data are presented as adjusted mean ± SE.  Chi square tests were used to 
determine gender and hormone replacement therapy (HRT) status frequency 
differences among genotype groups and to determine if genotype frequencies 
deviated from the expected Hardy-Weinberg equilibrium.  Baseline subject 
characteristics were compared between the IL6 GG, GC, and CC genotype groups 
using analysis of variance (ANOVA).  Where significant differences existed among 
groups, post-hoc tests were performed.  Analysis of covariance (ANCOVA) was used 
to compare baseline plasma lipoprotein-lipids and CRP levels among genotype 
groups with age, gender, HRT status, and body fat percentage as covariates.  
ANCOVA was used to compare plasma lipoprotein-lipid and CRP level changes with 
exercise training among genotype groups with age, gender, HRT status, change in 
body fat, and baseline value of the outcome variable as covariates.  Change with 
exercise training was calculated as the final outcome measure value minus the 
baseline outcome measure value (F-B).  Paired t-tests were used to analyze whole 
group and within genotype group changes in outcome measures with exercise 
training.  Sample size varied according to outcome measure as complete data were 
not available for all subjects.  The sample size for the entire group was 65 for 
conventional lipids and 52 for NMR plasma lipoprotein-lipid measures.  Sample size 
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by genotype group was as follows:  GG genotype group was 20 for conventional 
lipids and 17 for NMR measured lipids; GC genotype group was 30 for conventional 
lipids and 24 for NMR measured lipids; CC genotype group was 15 for conventional 
lipids and 11 for NMR measured lipids.  For CRP measures, sample size for the entire 
group was 29 for baseline and change with training measures.  By genotype group, 
sample size for baseline and change with training values was 10 for the GG group, 12 
for the GC group, and 7 for the CC group.  
With recent evidence suggesting that the current methods available for 
adjusting family-wise alpha error rate in gene association studies involving multiple 
phenotypes do not take into account the correlation among variables or allow only for 
conclusions to be made about multivariate composites of variables rather than 
specific variables, no adjustment of the p-value per test was made.5  Some protection 
against the relevance of family-wise alpha error rate is provided by the fact that the 
study hypotheses were made a priori based on specific functional relationships 
suggested between IL-6 and baseline blood lipids and blood lipid response to exercise 
training.32,46,74,105,106  Additionally, no multiple comparison tests were performed 
among genotype groups unless a significant genotype effect was found in the 
ANCOVA model, thus providing a protected test.    
A developing argument among researchers looking at gene*environment 
interactions involves the handling of potential confounding variables in the statistical 
analysis of the data.10,229,230,244  Many studies adjust for potential confounding factors 
with known biological influence on the gene product and/or outcome measure by 
including them in a statistical model as covariates without investigating whether a 
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significant gene*covariate interaction exists.  Another approach supports the 
inclusion of covariates only if a significant gene*covariate interaction exists for the 
outcome variable.  Analyses in the present study included covariates in the ANCOVA 
based on known biological influence of those covariates on both the gene product and 
the outcome measures.18,24,39,54,63,100,140,147,173,178,190,227  However, to explore the 
argument of only including covariates in a model when there is a significant 
gene*covariate interaction, a modified general linear backwards elimination model 
was used to test for significant interactions between IL6 genotype and each covariate 
included in the main ANCOVA analysis.  This analysis was performed for a 
representative group of the outcome variables (TC, TG, LDL-C, VLDL6, HDL-C, 
HDL2-C, HDL3-C, HDL5NMR-C, HDL4NMR-C, and integrated HDL4,5NMR-C).  The full 
model included all covariates, genotype, and all covariate*genotype interactions.  The 
model was reduced by eliminating the least significant interaction term.  All 
covariates and the IL6 genotype term remained in the model as they were not eligible 
for removal.  The procedure was stopped when the significance level of all remaining 
interaction terms was greater than p=0.05.  If a significant gene*covariate interaction 
term remained in the model, it was reported.  For a covariate that was a continuous 
variable, regression analysis was used to plot the relationship between the covariate 
and outcome variable by genotype at the mean values of the remaining covariates.  
For a covariate that was a categorical variable, the least squares means for the 
genotype were reported (adjusted for any unequal replication in the categorical 
variable).  
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Data analysis was limited to Caucasians due to the relatively small number of 
African American participants and their reported rare allele frequency of 0.08.94
Logarithmic transformation was performed on the change in HDL5NMR-C due to 
variance inequalities.  Statistical significance was set at p ≤ 0.05.  Statistical 
procedures were analyzed using SPSS 11.0.1 (SPSS, Inc., Chicago, IL) and SAS 8e 
(Carey, NC) software.  
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RESULTS
IL6 allele and genotype frequencies did not differ significantly from Hardy-
Weinberg expectations (Table 1) and were similar to those reported recently.23,53,94
Age, number of women and men, and percentage of women on HRT did not differ 
among genotype groups (Table 2).  
Baseline age, body weight, total body fat, and VO2max did not differ among 
IL6 genotype groups (Table 2).  No significant differences existed among genotype 
groups for baseline CRP levels, conventional lipid measures, or NMR-measured 
lipids (Tables 3-8).  However, while CRP levels were not significantly different 
among genotype groups (p=0.4), the G allele carriers showed higher CRP levels (GG 
= 2.8 ± 0.7 mg/L and GC = 2.9 ± 0.7 mg/L) and noncarriers of the G allele lower 
CRP levels (CC = 1.5 ± 0.9 mg/L) (Table 3).  
With exercise training, total body fat decreased and VO2max increased 
similarly among genotype groups (Table 2).  Within group weight change with 
exercise training was not significant for the CC group (-0.1 ± 0.7 kg) but was 
significant for the GG (–2.0 ± 0.5 kg, p<0.001) and GC (-0.9 ± 0.4 kg, p=0.03) 
groups.  Among genotype groups, the CC group reduction in body weight was 
significantly less than the GG group (p=0.05), but the GC group reduction was not 
significantly different from either the GG or the CC groups.  Significant differences 
existed among genotype groups for change with exercise training in HDL-C, HDL3-
C, HDL5NMR-C, HDL4NMR-C, integrated HDL4,5NMR-C, and HDLsize (Tables 4,5, and 
9).  For HDL-C, the CC group increased significantly more than both the GG (7.0±
1.3 v. 1.0 ± 1.1 mg/dL, p=0.001) and the GC group (3.3 ± 0.9 mg/dL, p=0.02).  For 
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HDL3-C, the CC group increased significantly more than both the GG (6.1 ± 1.0 v. 
0.9 ± 0.9 mg/dL, p<0.001) and the GC group (2.5 ± 0.7 mg/dL, p=0.006).  For 
HDL5NMR-C, the change with training for the CC group was significantly greater than 
the GC group (3.4 ± 1.0 v. 0.0 ± 0.7 mg/dL, p=0.02).  The GG group also had a 
significantly greater increase in HDL5NMR-C than the GC group (1.4 ± 0.8 v. 0.0 ± 0.7 
mg/dL, p=0.04) (Table 9).  For HDL4NMR-C, the CC group changed significantly 
differently from the GG group with the CC group increasing and the GG group 
decreasing HDL4NMR-C  (3.2 ± 1.3 v. -0.4 ± 1.1 mg/dL, p=0.05).  The GC group also 
differed significantly from the GG group with the GC group increasing HDL4NMR-C 
(3.1 ± 0.9  v. -0.4 ± 1.1 mg/dL, p=0.05 (Table 9).   For integrated HDL4,5NMR-C, the 
CC group increased significantly more than the GG group (6.5 ± 1.6 v. 1.0 ± 1.3 
mg/dL, p=0.01) (Table 9).  For HDLsize, the CC group increased significantly more 
than both the GG (0.3 ± 0.1 v. 0.1 ± 0.1 mg/dL, p=0.02) and GC groups (0.0 ± 0.0 
mg/dL, p=0.007) (Table 9).  
No significant differences were evident among genotype groups for change 
with exercise training in CRP levels (Table 3), in TC, LDL-C, TG, or HDL2-C 
measures (Table 4), or change in various lipoprotein lipid subfractions (intermediate-
density lipoproteins (IDL), LDL1-3-C, VLDL1-6-TG,  HDL3NMR-C, HDL2NMR-C, 
HDL345NMR-C, HDL12NMR-C, VLDLsize, LDLsize, and LDL[particle] )(Tables 5-8).    
The gene*covariate interaction analysis resulted in two significant interactions 
for one outcome measure.  The outcome was change in integrated HDL4,5NMR-C, and 
the interactions were genotype*gender-HRT status (p=0.03) (Figure 1) and 
genotype*change in body fat (%) (p=0.01) (Figure 2).  Plot estimates were based on 
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least squares means at AGE = 57.71154, change in body fat (%) = -1.18269, and 
baseline HDL4,5NMR-C = 15.64038.
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Table 1.  IL-6 –174 G/C promoter polymorphism allele and genotype 
frequencies
-174 G/C Allele       Genotype Frequency χ
G            C GG GC CC χ=.33
Total Study 0.54        0.46 0.31 (20) 0.46 (30) 0.23 (15) p=.56
CRP Sample G            C GG GC CC χ=.77
0.55        0.45 0.34 (10) 0.41 (12) 0.24 (7) p=.38
NMR Lipid 
Sample G            C GG GC CC χ=.22
0.56        0.44 0.33 (17) 0.46 (24) 0.21 (11) p=.64
Numbers in parentheses are actual sample sizes (n).
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Table 2.  Subject characteristics:  baseline and change with exercise training
IL6 -174G/C Genotype Group
Characteristics Total GG GC CC P
Age (yrs) 57.9 ±  0.7 57.9 ±  1.3 57.7 ±  1.0 58.5 ±  1.5 NS
Female/Male 41/24 11/9 20/10 10/5 NS
% Females on HRT 54% (22) 55% (6) 55% (11) 50% (5) NS
Weight (kg)
 Baseline 80.0 ±  2.0 81.6 ±  4.3 78.7 ±  1.0 78.4 ±  3.3 NS
    Change -1.1 ±  0.3* -2.0 ±  0.5* -0.9 ±  0.4* -0.1 ± 0.7† 0.05
Body fat (%)
    Baseline 37.0 ±  1.1 36.5 ±  2.1 36.7 ± 1.4 38.1 ± 2.9 NS
    Change -1.3 ±  0.2* -2.0 ±  0.4* -0.8 ± 0.3* -1.4 ±  0.6* NS
VO2max (L/min)
    Baseline 2.0 ± 0.1 2.1 ±  0.2 2.0 ± 0.1 1.9 ± 0.1 NS
    Change 0.3 ±  0.0* 0.3 ±  0.0* 0.3 ±  0.0* 0.2 ±  0.0* NS
VO2max (mL/kg/min)
    Baseline 25.0 ±  0.6 25.4 ±  1.3 25.2 ± 0.7 24.1 ± 1.3 NS
Change 3.9 ±  0.3* 4.9 ±  0.7* 3.5 ± 0.5* 3.2 ± 0.4* NS
Values are expressed as adjusted means ± SE except for frequency data.  
Sample size:  total =65; GG=20; GC=30; CC=15.
* Indicates significant change within group after training p<0.01.  
P = statistical probability for the difference among genotype  groups.
† = CC significantly different from GG.
Change = Change with exercise training (F-B).
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Table 3.  CRP measures:  baseline and change with exercise training
IL6 Genotype Group
Total GG GC CC P
CRP (mg/L)
    Baseline  2.4 ± 0.4
 (n=29)
 2.8 ± 0.7
 (n=10)
 2.9 ± 0.7
 (n=12)
 1.5 ± 0.9
 (n=7)
0.43






 0.2 ± 0.6
 (n=6)
0.73
Values are expressed as adjusted means ± SE.  
* Indicates significant change within group after training p<0.05. 
P = statistical probability for the difference among genotype groups.  
Change = Change with exercise training (F-B).  
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Table 4.  Conventional lipids:  baseline and change with exercise training
IL6 Genotype Group
Total GG GC CC P
Total-C      
    Baseline 211.1 ± 4.4 207.9 ± 7.6 209.6 ± 6.2 215.9 ± 8.8 NS
    Change -0.6 ± 2.5 -7.7 ± 4.4 -  1.1 ± 3.6 6.9 ± 5.2 NS
LDL-C      
    Baseline 131.7 ± 3.7 124.6 ± 6.4 130.9 ± 5.2 139.7 ± 7.4 NS
    Change     0.2 ± 2.4 -6.2 ± 4.3     2.1 ± 3.5     4.7 ± 5.1 NS
Triglycerides
    Baseline 157.0 ± 9.2 167.6 ± 16.0 153.6 ± 13.1 149.7 ± 18.5 NS
    Change -12.2 ± 4.8* -7.0 ± 8.4 -13.7 ± 6.8* -16.0 ± 9.8 NS
HDL-C      
    Baseline 47.7 ± 1.7 49.9 ± 3.0 45.8 ± 2.4 47.4 ± 3.4 NS
    Change   3.8 ± 0.6*   1.0 ± 1.1   3.3 ± 0.9*   7.0 ± 1.3*† 0.003
HDL2-C      
    Baseline 5.1 ± 0.9 7.4 ± 1.5 4.1 ± 1.3 3.9 ± 1.8 NS
    Change 0.9 ± 0.4* 0.0 ± 0.6 0.6 ± 0.5 2.1 ± 0.7* NS
HDL3-C      
    Baseline 42.5 ± 1.0 42.4 ± 1.8 41.9 ± 1.5 43.1 ± 2.1 NS
    Change   3.2 ± 0.5*   0.9 ± 0.9   2.5 ± 0.7*   6.1 ± 1.0*† 0.001
Values are expressed as adjusted means (mg/dL) ± SE.  
Sample size:  total =65; GG=20; GC=30; CC=15.
* Indicates significant change within group after training p<0.05.  
P = statistical probability for differences among genotype groups.
† = CC significantly different from CG and GG (see Table 9).
Change = Change with exercise training (F-B).
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Table 5.  NMR measured HDL-C lipids:  baseline and change with exercise 
training
IL6 Genotype Group
Total GG GC CC P
HDL5NMR
    Baseline   5.3 ± 1.0   6.4 ± 1.6   4.0 ± 1.4   5.5 ± 2.0 NS
    Change   1.6 ± 0.5*   1.4 ± 0.8   0.0 ± 0.7†   3.4 ± 1.0* 0.03
HDL4NMR
    Baseline 10.9  ± 0.9 10.7 ± 1.   9.6 ± 1.3 12.5 ± 2.0 NS
    Change   2.0  ± 0.6* -0.4 ± 1.1   3.1 ± 0.9*   3.2 ± 1.3 0.04
HDL3NMR
    Baseline 11.4  ± 1.3 12.8 ± 2.2 12.7 ± 1.8 8.6 ± 2.7 NS
    Change -0.3 ± 0.8   1.2 ± 1.3 -1.8 ± 1.1 -0.3 ± 1.6 NS
HDL2NMR
    Baseline 14.4  ± 1.0 13.9 ± 1.7 12.9 ± 1.4 16.4 ± 2.1 NS
    Change -0.0 ± 0.7 -0.9 ± 1.1   1.3 ± 0.9 -0.4 ± 1.4 NS
HDL3,4,5NMR
    Baseline 27.5 ± 2.0 29.8 ± 3.3 26.3 ± 2.8 26.5 ± 4.1 NS
    Change   3.5 ± 1.2*   1.9 ± 2.0   1.1 ± 1.7   7.5 ± 2.4* NS
HDL4,5NMR
    Baseline 16.2 ± 1.6 17.0 ± 2.7 13.6 ± 2.3 18.0 ± 3.4 NS
    Change   3.6 ± 0.8*   1.0 ± 1.3   3.3 ± 1.1*   6.5 ± 1.6* 0.04
HDL1,2NMR
    Baseline 15.9 ± 1.0 15.3 ± 1.6 14.2 ± 1.4 18.1 ± 2.0 NS
    Change   0.0 ± 0.6 -0.5 ± 1.1   0.9 ± 0.9 -0.4 ± 1.4 NS
Values are expressed as adjusted means (mg /dL) ± SE.
Sample size:  total =52; GG=17; GC=24;CC =11.
* Indicates significant change within group after training p<0.05.  
P = statistical probability for the difference among genotype groups.
†= GC significantly different from CC and from GG.
Change = Change with exercise training (F-B).
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Table 6.  NMR measured LDL-C lipids:  baseline and change with exercise training
IL6 Genotype Group
Total GG GC CC P
IDL
    Baseline   1.9 ± 0.7   3.1 ± 1.2   1.8 ± 1.0   0.7 ± 1.5 NS
    Change -0.9 ± 0.4 -0.1 ± 0.6 -1.2 ± 0.6 -1.7 ± 0.9 NS
LDL3
    Baseline 52.7 ± 6.7 48.1 ± 11.2 45.9 ± 9.4 64.2 ± 13.8 NS
    Change 10.6 ± 4.1* -1.8 ± 7.0 13.1 ± 5.8* 20.5 ± 8.6 NS
LDL2
    Baseline 36.4 ± 5.4 30.3 ± 9.1 38.3 ± 7.6 40.6 ± 11.2 NS
    Change -3.5 ± 4.3 -7.3 ± 7.3 -0.7 ± 6.1 -2.5 ± 8.9 NS
LDL1
    Baseline 42.5 ± 6.6 49.4 ± 11.1 41.5 ± 9.3 36.4 ± 13.7 NS
    Change -7.4 ± 5.1 1.8 ± 8.8 -7.1 ± 7.3 -16.9 ± 10.6 NS
Values are expressed as adjusted means (mg/dL) ± SE.  
Sample size:  total =52; GG=17; GC=24;CC=11.
* Indicates significant change within group after training p<0.05. 
P = statistical probability for difference among genotype groups.
Change = Change with exercise training (F-B).  
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Table 7.  NMR measured VLDL-TG:  baseline and change with exercise training
IL6 Genotype Group
Total GG GC CC P
VLDL6NMR
    Baseline 10.3 ± 4.2 13.5 ± 7.1 11.3 ± 6.0   6.2 ± 8.8 NS
    Change -5.5 ± 1.9   1.3 ± 3.2 -7.9 ± 2.6 -9.9 ± 3.9 NS
VLDL5NMR
    Baseline 30.2 ± 4.7 37.6 ± 8.0 30.8 ± 6.7 22.1 ± 9.8 NS
    Change -3.0 ± 4.0 12.3 ± 7.0 -5.2 ± 5.7 -16.0 ± 8.4 NS
VLDL4NMR
    Baseline 43.0 ± 3.5 44.2 ± 5.8 45.2 ± 4.9 39.7 ± 7.2 NS
    Change -6.5 ± 2.5* -7.5 ± 4.3 -3.2 ± 3.6 -8.8 ± 5.2 NS
VLDL3NMR
    Baseline   2.6 ± 0.8   2.3 ± 1.3  2.4 ± 1.2   3.2 ± 1.6 NS
    Change   1.1 ± 1.1   1.8 ± 2.0 -0.2 ± 1.6   1.7 ± 2.4 NS
VLDL2NMR
    Baseline 13.0 ± 1.9   9.8 ± 3.2 17.5 ± 2.7 11.8 ± 3.9 NS
    Change -0.3 ± 1.7 -3.9 ± 3.0   2.2 ± 2.5   2.0 ± 3.6 NS
VLDL1NMR
    Baseline 15.1 ± 2.6 14.7 ± 4.3 10.7 ± 3.6 20.0 ± 5.3 NS
    Change -1.2 ± 1.9   0.8 ± 3.2 -1.3 ± 2.7 -3.1 ± 4.0 NS
Values are expressed as adjusted means (mg/dL) ± SE.  
Sample size:  total =52; GG=17; GC=24;CC=11.
* Indicates significant change within group after training p<0.05.  
P = statistical probability for difference among genotype groups.
Change = Change with exercise training (F-B).  
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Table 8.  NMR measured particle size:  baseline and change with exercise training
IL6 Genotype Group
Total GG GC CC P
VLDLsize
    Baseline      48.7 ± 1.6      50.0 ± 2.7      50. ± 2.3     45.5 ± 3.3 NS
    Change -2.0 ± 1.3 -1.4 ± 1.9 -1.4 ± 1.9 -5.7 ± 2.8 NS
LDLsize
    Baseline      20.6 ± 0.1      20.5 ± 0.2     20.5 ± 0.2     20.9 ± 0.2 NS
    Change        0.2 ± 0.8* -0.0 ± 0.1       0.2 ± 0.1       0.4 ± 0.2 NS
HDLsize
    Baseline       8.7 ± 0.1        8.8 ± 0.1       8.7 ± 0.1       8.7 ± 0.1 NS
    Change       0.1 ± 0.0*        0.1 ± 0.1       0.0 ± 0.0       0.3 ± 0.1*† 0.02
LDL[particle]
    Baseline    1570 ± 71     1572 ± 119    1518 ± 100    1620 ± 147 NS
   Change -63 ± 43 -62 ± 73          8 ± 61 -135 ± 89 NS
Values are expressed as adjusted means (nm) ± SE.  
Sample size:  total =52; GG=17; GC=24;CC=11.
* Indicates significant change within group after training p<0.05.  
P = statistical probability for difference among genotype groups.
† = CC significantly different from CG and GG.
Change = Change with exercise training (F-B).
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Table 9.  Significant differences in HDL-C and HDL-C subfraction changes with 
exercise training among genotype groups 
IL-6 Genotype Group
GG GC CC P
HDL-C 
CC v. GC 3.3 ± 0.9* 7.0 ± 1.3* 0.02
CC v. GG 1.0 ± 1.1 7.0 ± 1.3* 0.001
HDL3-C 
CC v. GC 2.5 ± 0.7* 6.1 ± 1.0* 0.006
CC v. GG 0.9 ± 0.9 6.1 ± 1.0* <0.001
HDL5NMR
GC v. CC 0.0 ± 0.7 3.4 ± 1.0* 0.02
GC v. GG 1.4 ± 0.8 0.0 ± 0.7 0.04
HDL4NMR
GG v. CC -0.4 ± 1.1 3.2 ± 1.3 0.05
GG v. GC -0.4 ± 1.1 3.1 ± 0.9* 0.02
HDL4,5NMR
CC v. GG 1.0 ± 1.3 6.5 ± 1.6* 0.01
HDLsize
CC v. GG 0.1 ± 0.1 0.3 ± 0.1* 0.02
CC v. GC 0.0 ± 0.0 0.3 ± 0.1* 0.007
Values are expressed as adjusted means (mg/dL or nm)  ± SE.
* Indicates significant change within group after training p<0.05. 
 P = statistical probability for difference among genotype groups.
Change = Change with exercise training (F-B).
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     Figure 2.  Change In Body Fat*IL6 Genotype Interaction For Exercise Training-






















































Figure 1.  Gender-Hormone Replacement Therapy*IL6 Genotype Interaction   
                For Exercise Training-Induced Change In HDL4,5NMR-C  (mg/dL)
    (p=0.03) 
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DISCUSSION
Plasma lipoprotein lipid levels are independent risk factors for CV 
disease.137,140,233  They are also a component of the innate inflammatory response 
thought to contribute to creating a hostile environment to fight infectious agents 
and/or provide substrates for energy metabolism, especially during times of 
starvation.47,49,54,68,105,106,131,144  Mediating the inflammatory response, the pro-
inflammatory cytokine IL-6 has also been independently associated with CV 
morbidity and mortality, as well as with variation in plasma lipoprotein lipid levels. 
9,46,77,126,133,187,188,226  Additionally, both lipids and IL-6 levels are highly variable 
among individuals, modifiable, and influenced by genetics, environmental factors, 
and the interaction among genetic and environmental 
factors.21,46,53,57,108,174,181,213,232,252  Thus, understanding these genetic and 
environmental factors is paramount to improving public health through CV disease 
risk reduction.  Contributing to this understanding, we found an association between 
the IL6 –174G/C promoter polymorphism and exercise training-induced changes in 
HDL-C, HDL3-C, HDL5NMR, HDL4NMR-C, integrated HDL4,5NMR-C, and HDLsize.  
These data suggest that IL6 genotype may interact with exercise training to influence 
changes in HDL-C and HDL-C subfractions.  
IL-6 is the primary cytokine regulating the acute phase response.12,239  It also 
directly influences other metabolic, endothelial, and coagulation factors.162,251,252  Of 
particular interest is the role of cytokines in inducing pro-atherogenic changes in 
lipoproteins and lipid metabolism.105,106  These changes include increased TG levels, 
VLDL-TG, and small dense LDL-C and decreased HDL-C levels.105,106  Additionally, 
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enzymes and apolipoproteins associated with HDL-C and its anti-inflammatory, anti-
oxidant, and reverse cholesterol transport functions undergo changes with 
inflammation that may inhibit the normal protective effect of HDL-C against 
atherosclerosis.11,105,106  These changes include decreased lecithin:cholesterol 
acyltransferase (LCAT), cholesterol ester transfer protein (CETP), hepatic lipase 
(HL), and phospholipid transfer protein (PLTP) activity, decreased HDL and apo A-I 
levels, and increased serum amyloid A (SAA), and apo J.105,106  While this response is 
helpful in fighting infection and injury and providing substrates for energy 
metabolism, chronically elevated levels of IL-6 and subsequent metabolic effects can 
be detrimental.47,49,105,106,131,144,252  Recent evidence shows chronic elevation of IL-6 
can result from environmental factors (stress, pollution, smoking), metabolic factors 
(chronic infection, tissue injury, obesity), and genetic factors.252  Thus, regardless of 
the cause (host defense or other factors), elevated IL-6 may result in deleterious 
alterations in lipids and lipid metabolism.
Polymorphisms in the promoter region of the IL6 gene have been associated 
with alterations in IL6 gene transcription and IL-6 protein levels.23,51-
53,57,98,146,225,232,242  Studied in relation to CV disease, these polymorphisms include the 
–597G/A, -572 G/C, -373AnTn, and –174G/C promoter polymorphisms.
23,51-
53,57,98,146,225,232,236,242  Of these, the –174G/C polymorphism is the most well-studied 
and supported as a marker for the most frequently described haplotypes, as well as 
being associated with IL-6 levels and such health related phenotypes as diabetes, 
glucose and insulin homeostasis, hypertension, body composition, and lipid 
profiles.9,44,46,49,50,93,127,133,138,226,242,243
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After controlling for a number of covariates, we found no significant 
differences in baseline levels of conventionally measured lipids and lipid subfractions 
and no differences in NMR measured subfractions among IL6-174G/C genotype 
groups.  However, though not statistically significant, the GG genotype group had the 
lowest TC and LDL-C levels versus the CC group, higher TG, HDL-C, and HDL2-C 
levels than the GC and CC groups, and lower HDL3-C than the CC group.  In terms 
of baseline NMR measured subfractions, we found that the GG group generally had a 
less atherogenic lipoprotein lipid profile than the CC group.  Though not statistically 
significant, levels of the surrogate marker CRP tended to be higher in carriers of the 
G allele than the CC group as expected.  Although the lipid findings are not 
statistically significant nor can they be generalized, they could suggest a somewhat 
less atherogenic baseline lipid profile for the GG group compared to the CC group, a 
finding opposite of what we hypothesized.
Suggesting a less atherogenic baseline lipid profile for the GG genotype 
group, the findings in this study differ from other studies that found associations 
between IL6 genotype and baseline fasting lipid levels.9,46,133,226  For example, 
Fernandez Real et al.46 found an association between carriers of the G allele and 
increased TG, VLDL-TG, and apo B, decreased HDL2-C, and a tendency toward 
higher IL-6 levels.  In epidemiological studies, Mendall et al.133 found that in men 
with various CV disease risk factors, higher IL-6 levels were associated with 
increased plasma TG concentrations.  Baggio et al.9 found that higher IL-6 levels in 
healthy centenarians were associated with relatively high plasma TG and low HDL-C.  
Thus, these studies suggest that individuals prone to higher IL-6 production are more 
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likely to develop higher TG, VLDL-TG, plasma free fatty acids (FFA), and lower 
HDL2-C than those with  lower IL-6 levels.  With the G allele associated with higher 
IL-6 levels, carriers of the G allele would appear more susceptible to lipid 
abnormalities and thus a more pro-atherogenic lipid profile.46  Using CRP as a 
surrogate measure of IL6 levels, this investigation found a tendency for the G allele 
carriers to have non-significantly higher baseline CRP levels compared to the CC 
homozygotes.  Additionally, the G allele carriers tended to have higher, though not 
significantly different, levels of  TG, VLDL6NMR, VLDL5NMR, and VLDL4NMR than 
the CC homozygotes.  Though not statistically significant, the results are of interest as 
they suggest possible support for the association of higher IL6 levels and somewhat 
more atherogenic TG related lipid measures in carriers of the G allele as compared to 
the CC homozygotes.  In contrast, while the TG related measures are of interest, the 
overall baseline lipid profile did appear less atherogenic for the G allele carriers.   
Viewed from an evolutionary perspective, the results from this study and 
others suggesting an association between genotype, higher IL6 levels, and lipid 
abnormalities are plausible.47,49,54,131,133,144,252  The common G allele, associated with 
higher IL-6 levels, would represent an advantageous adaptation to an historic 
environment of infection, injury, intermittent feeding, and short life 
expectancy.44,47,53,113,131,144  However, this advantage is lost in a Westernized society 
marked by little physical activity, high fat processed foods, and abundant 
feeding.47,131,144  Why the baseline profile of the GG group in our study reflected the 
expected higher TG, VLDL6NMR, VLDL5NMR, VLDL4NMR, and LDL1NMR, but not a
significantly different and more atherogenic lipid profile overall than the CC 
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genotype group, is not clear.  The lack of expected findings may be due to sample 
size issues resulting in lack of detection of a genotype effect.  It is also plausible that 
our initially sedentary subjects did not possess levels of IL-6 that were elevated to the 
point of inducing striking differences in lipid profiles among gentoype groups.  
Additionally, with such a complex interplay among various physiological systems 
and environmental factors influencing lipid levels, a single gene analysis may not 
adequately reflect the physiology determining lipid levels and suggests that perhaps 
this polymorphism is in linkage disequilibrium with others in the IL6 gene that affect 
protein function rather than levels or with other genes that influence transcription.241
Another limitation to the interpretation of these results is the lack of direct measures 
of IL-6 levels for analysis by genotype group and association with lipid levels.  It is 
possible that the genotype groups in this study would not reflect higher IL-6 levels in 
carriers of the G allele, even though the CRP measures suggest that they would.  
Thus, additional studies involving additional subjects, direct measures of IL-6, and
including investigation of the functional steps potentially influenced by IL-6 (lipid 
metabolism related enzyme activities) are needed.
Endurance exercise training is known to influence lipid levels and appears to 
influence IL-6 levels.17,19,20,34-38,42,69,70,73,74,84,89,91,97,101,103,114-117,149,153,154,168-
172,181,193,207,221,223,234,249  Genetic factors are known to interact with exercise training to 
influence lipid response, while the interaction of IL6 genotype with exercise training 
is not known in terms of its influence on IL-6 and lipid levels.  Using CRP levels as 
surrogate indicators of IL-6 levels, no significant changes in CRP levels were found 
with exercise training, nor were any significant differences found among genotype 
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groups in terms of change in CRP with exercise training.  However, the results did 
show that while the CC group increased and the GG group decreased, the GC group 
decreased plasma CRP levels the most.  We did find significant differences among 
genotype groups in exercise training-induced changes in HDL-C, HDL3-C, HDL5NMR-
C, HDL4NMR-C, integrated HDL4,5NMR-C, and HDLsize in which the CC group 
demonstrated the greatest beneficial increases in HDL-C measures.  In all cases 
except HDL5NMR-C, the CC group differed significantly from the GG group.  For 
HDL-C, HDL3-C, and HDLsize, the CC group also differed significantly from the GC 
group.  For HDL5NMR-C, the CC group differed from the GC group, and the GG 
group differed from the GC group.  With exercise training producing increases in 
these HDL-C measures for the CC group, the changes can be viewed as more 
advantageous for the less common allele.  This could suggest a more advantageous 
gene-environment interaction for IL6 CC genotype and exercise training in improving 
HDL-C levels.  With HDL-C being an important molecule in resisting CV disease 
through its anti-inflammatory, anti-coagulatory, and anti-oxidant properties, such 
changes in HDL would prove beneficial.  
In light of the analysis of the multiple lipoprotein lipid categories and their 
subfractions, the consistency of direction and variables that were statistically 
significant provide support for the biological plausibility that the IL6 –174G/C 
polymorphism may be associated with exercise training-induced changes in HDL- C 
and various HDL-C subfractions.  This consistency provides support for the 
conclusion that the findings were not merely the result of chance due to multiple 
comparison testing.  The significance levels for the significant findings among 
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genotype groups were ≤ 0.007 in four cases, ≤ 0.02 in five cases, and ≤ 0.05 in two 
cases, demonstrating that over one-third of the findings would remain statistically 
significant even with the adoption of an extremely conservative significance level.  
These findings also occurred entirely in the HDL-C category and were consistent in 
terms of the groups that differed and the direction in which they changed.  While this 
consistency in significant findings in only the HDL-C outcome variables could be 
argued as having resulted from the correlation among those variables, the lack of 
significant findings in the other lipoprotein lipid categories, inter-correlated with each 
other and the HDL-C measures as well, suggests that, if the results were due to 
correlation, significant findings should have been found in the other lipoprotein 
categories as well.  Additionally, the study hypotheses were made a priori based on 
specific functional relationships suggested between IL-6 and baseline blood lipids and 
blood lipid response to exercise training.5,9,32,46,74,133,226  Thus, the findings are 
supported both biologically and statistically and demonstrate an association between 
the IL6–174G/C polymorphism and exercise training induced changes in HDL-C and 
HDL-C subfractions. 
With the argument growing regarding the use of covariates in the statistical 
models used in gene association studies, this study included the analysis of 
gene*covariate interactions by outcome measure.10,229,230,244  This analysis resulted in 
two significant interactions (gender-HRT status*genotype, p=0.03, and change in 
body fat*genotype, p=0.01) in one outcome measure (change in HDL4,5NMR-C).  The 
findings suggest that for women on HRT, the GG genotype group resulted in a 
decrease in HDL4,5NMR-C while the GC and CC groups increased HDL4,5NMR-C.  This 
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suggests a more advantageous response for the C allele carriers.  For women not on 
HRT, genotype appeared less influential.  For men, all genotype groups increased 
HDL4,5NMR-C, a favorable response.  For the change in body fat percentage*IL6 
genotype interaction, the data suggest that genotype was more influential for the 
homozygote groups.  For example, in the CC group, a greater reduction in body fat 
percentage resulted in a smaller increase in integrated HDL4,5NMR-C.  In contrast, the 
prediction in the GG group is that a greater than 1% reduction in body fat percentage 
is required for an increase in HDL4,5NMR-C.  For the heterozygotes, the change in 
integrated HDL4,5NMR-C was essentially the same across the range of changes in body 
fat percentage.  Thus, these analyses demonstrate that interactions between genotype 
and covariate are of interest.      
As little research has been done on the effect of exercise training on IL-6 
levels, and no research has been conducted on the interactive effects of IL6 genotype 
and exercise training on IL-6 levels, any potential mechanisms that could be driving 
the association between HDL-C changes and IL-6 genotype are not known.  While 
some evidence does suggest that perhaps exercise training can attenuate the 
inflammatory response and that it may lower IL-6 levels in heart patients and healthy 
older adults, additional research is needed.3,13,59,177,235  Following the notion of the 
“thrifty gene” hypothesis, it is plausible that the less common C allele would reflect a 
“lower responder” in terms of IL-6 release.47,49,131,144  As such, exercise induced 
increases may be lower as well.  However, it has been shown that the exercise 
induced increase in IL-6 comes from contracting skeletal muscle with the majority of 
the secretion coming from myocytes themselves.88,224  This IL-6 may be functionally 
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different from the immune or inflammatory induced release of IL-6 from other 
cells.88,170,224,238  Thus, it is not known if the exercise-induced IL-6 secretion from 
skeletal muscle possesses the same proatherogenic functions of the inflammatory 
response induced IL-6 secretion.  Perhaps the IL-6 secreted in response to different 
stimuli reflects the operation of different physiological pathways designed to exert 
specific effects – one primarily immunological and one primarily for energy 
regulation. 88,170,224,238  Additionally, a recent study showed that IL-6 deficient mice 
had less endurance capacity and energy expenditure during exercise, suggesting that 
IL-6 release is essential to normal exercise capacity.40  This finding, while not in 
humans, might suggest that individuals with CC genotype, associated with lower IL-6 
production, could have lower exercise capacity and perhaps have attenuated release of 
IL-6 with exercise.  Whether this would then affect resting IL-6 levels is unclear.  
Nevertheless, it is plausible that the less common C allele is associated with a more 
positive change in HDL should the exercise training interact with the lower 
responding genotype to produce lower levels of IL-6 and thus produce fewer 
disadvantageous changes in the lipid profile.  Again, if viewed in terms of the “thrifty 
gene hypothesis”, G allele carriers would be expected to reflect higher IL-6 
production and to have a stronger response to stimulatory factors than those with a 
CC genotype.  Hence, with exercise training, perhaps this stronger response is 
maintained in which G allele carriers continue to have higher levels and to reflect a 
less beneficial effect of the exercise training in terms of HDL-C change with training.  
Thus, while the findings of this study were in contrast to other studies finding 
an association of the G allele with a more pro-atherogenic baseline lipid profile, the 
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significant differences among genotype groups in terms of HDL-C changes with 
exercise training are novel and provide preliminary data of interest for future 
investigation of the gene*exercise training interaction in regard to IL-6 genotype.  
The lack of consistency in findings may lie in the multi-functional nature of the IL-6 
molecule itself whereby it may be difficult to discern the effect of the IL-6 secreted in 
response to different stimuli.  It is also plausible that the use of CRP as a surrogate 
marker may not adequately reflect the exercise training effect on IL-6 levels and calls 
for additional studies employing the direct measure of IL-6 levels.      
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CONCLUSIONS
In summary, the present findings provide further evidence for the association 
of IL6 genotype with plasma lipoprotein lipid levels, particularly with the change in 
HDL-C and its subfractions with endurance exercise training.  Major strengths of this 
study include control of dietary composition and baseline physical activity level, a 
highly standardized prolonged endurance exercise training program, the NMR 
analyses of plasma lipoprotein lipid subfractions, and the investigation of the 
interaction of IL6 genotype and endurance exercise training.  However, the 
limitations of this study are the lack of direct measurement of IL-6 levels and the lack 
of sample size to perform haplotype analyses.  While these limitations reduce 
generalizability, the findings in this study do provide support for additional 
investigation of the IL-6 promoter polymorphisms and their interaction with 
endurance exercise training to affect change in plasma lipoprotein lipid profiles.  
With evidence mounting that IL-6 plays a major role in the initiation and progression 
of CV disease and in energy regulation, the investigation of potential functional 
variants in the IL6 gene and their interaction with endurance exercise training may 
prove useful to clinicians and paramount to public health officials in the fight against 
CV disease.
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REVIEW OF THE LITERATURE
Introduction
Cardiovascular (CV) disease is the leading cause of death in the Western 
world and will soon be the most critical health problem worldwide.7,137,190,192
Traditionally, the disease has been characterized as a lipid disorder in which excess 
lipid in the bloodstream accumulates in the arterial walls, resulting in CV disease.60-
62,119-123,135,190,196,197,199,200,203,252  Additionally, the risk of developing CV disease has 
been assessed based on the evaluation of such conventional risk factors as 
dyslipidemia, hypertension, age, gender, smoking status, diabetes status, physical 
inactivity, and obesity.6,7  However, recent research has focused on novel risk factors 
that may play a role in the development of CV disease, including factors related to the 
normal physiological processes involved in coagulation and fibrinolysis, endothelial 
function, and inflammation.60-62,118-122,124,125,165,185,185,189,190,192,251  The importance of 
such research is highlighted by the fact that many individuals presenting with CV 
disease and coronary events do not have traditional risk factors.182-184,186,190-192  One 
major line of this recent CV disease research focuses on the role of inflammation in 
the development of the disease.60-62,118-122,124,125,165,185,187,189,190,192,199  This research 
advances the theory that atherosclerosis is itself an inflammatory condition in which 
specific molecular and cellular responses occur, including elevation of levels of the 
inflammatory cytokine interleukin-6 (IL-6), which combined with lipid deposition, 
endothelial dysfunction, and smooth muscle cell and fibrous material accumulation, 
result in atherogenesis.60-62,118-120,122,123,135,183,190,192,198,252  Thus, current research 
suggests that a chronic inflammatory state, induced by some initiating factor and 
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characterized by elevated levels of IL-6, may provide the link between the 
development of the many poor health phenotypes classified as CV disease risk factors 
and the manifestation of the disease.60-62,118-120,122,123,183,190,192,198,252  More specifically, 
although inconclusive, evidence supports an association between circulating levels of 
the inflammatory cytokine IL-6 and plasma lipoprotein lipid levels, thus providing an 
additional potential mechanism through which IL-6 may be associated with the 
development of CV disease.9,46,56,128,133,143,163,164,176,226,238,254
Fortunately, CV disease risk can be reduced through such lifestyle 
modifications as exercise training.165,233  For example, exercise training is known to 
improve lipid profiles, although the response to training is highly variable and subject 
to environmental and genetic influences.21,35,38,85,109,110,114,115,117,141,181,195  However, 
the interactive effects of exercise training and IL6 genotype on IL-6 levels and 
subsequently plasma lipoprotein lipid levels are not known and call for additional 
research to ultimately discern the potential role of IL-6 in CV disease development.
The Inflammatory Response, Lipid Metabolism, and CV Disease
Historically, the human physiological response to environmental threats, 
including infection, injury, and starvation, has involved the induction of the 
inflammatory response and concomitant alterations in 
metabolism.11,45,47,49,54,65,68,76,105,106,128,131,133,144,252  These physiological changes were 
designed to protect the body from invading organisms, facilitate repair of damaged 
tissue, and to help prevent further injury and included increased levels of 
inflammatory cytokines (interleukin-1, tumor necrosis factor-α, IL-6), increased 
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levels of positive acute-phase proteins (CRP, serum amyloid A), decreased levels of 
negative acute-phase proteins (albumin, transferrin), and pro-atherogenic alterations 
in lipid metabolism.105,106  While these responses are protective and promote human 
survival in the short-term, the prolonged presence of these metabolic changes could 
be detrimental to human health.47,49,54,144,252  As the major regulator of this response, 
IL-6 may prove to be the link between many CV disease risk factors and development 
of the disease itself.252
As part of the inflammatory response, lipid metabolism and concentrations of 
plasma lipoproteins and lipids undergo pro-atherogenic changes.76,105,106  These 
potentially proatherogenic changes include increased TG, VLDL-TG, and small 
dense LDL-C levels and decreased HDL-C levels.76,105,106  Additionally, enzymes and 
apolipoproteins associated with HDL-C and its anti-inflammatory, anti-oxidant, and 
reverse cholesterol transport functions undergo changes with inflammation that may 
inhibit the normal protective effect of HDL-C against athersclerosis.11,76,105,106  These 
changes include decreased LCAT, CETP, HL and PLTP activity, decreased HDL and 
apo A-I levels, and increased SAA and apo J.76,105,106  These changes and their effects 
are summarized in the following table.106
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POTENTIAL CHANGES IN LIPIDS AND
LIPID METABOLISM DURING INFECTION AND INFLAMMATION
HDL Change Effect
HDL and apo A-I ↓ Impaired apolipoprotein-mediated cell cholesterol removal
LCAT ↓ Impaired cholesterol removal from cells by diffusion
CETP ↓ Impaired cholesterol transfer to triglyceride-rich lipoprotein
HL ↓ Reduced pre-beta HDL generation
PLTP ↓ Reduced pre-beta HDL generation; decreased HDL
phospholipid content and impaired cholesterol removal by
increasing cholesterol flux from HDL into cells
SAA ↑ Decreased availability of cholesterol in HDL to be metabolized
by hepatocytes; increased cholesterol uptake by macrophages
sPLA2 ↑ Decreased HDL phospholipid content and impaired cholesterol
removal by increased cholesterol flux from HDL into cells
PAF-AH activity ↑ Increased lysophosphatidycholine
PON ↓ Decreased anti-oxidant function of HDL (-LDL oxidation)
transferrin ↓ Impaired anti-oxidant function of HDL (- LDL oxidation) 
apo J ↑ Increased smooth muscle cell differentiation in arterial wall
LDL Change Effect
Small dense LDL ↑ Increased susceptibility to oxidation; increased penetration of 
LDL into endothelium; increased interaction with arterial wall
proteoglycans and LDL retention in arterial wall
PAF-AH activity ↑ Increased lysophosphatidycholine
sPLA2 ↑ Released polyunsaturated fatty acids from phospholipids that 
can be oxidized
Sphingolipid content ↑ Facilitated LDL aggregation and uptake by macrophages
Ceruloplasmin ↑ Increased oxidation of LDL
VLDL Change Effect
VLDL levels ↑
Increased availability of lipid substrates for macrophage 
uptake
LPL and HL ↓ Decreased triglyceride-rich lipoprotein clearance
Sphingolipid content ↑ Decreased triglyceride-rich lipoprotein clearance
Tissue apo E expression ↓ Decreased lipoprotein clearance
Khovidhunkit, W., Memon, R.A., Feingold, K.R., and C. Grunfeld.  Infection and 
inflammation-induced proatherogenic changes of lipoproteins.  The Journal of Infectious
Diseases.  181(Suppl 3):S462-72, 2000.
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As the major regulator of the inflammatory response, IL-6 may play a role in 
initiating some of these alterations in lipids and lipid metabolism.27,80,82,87,162,239
Systemically, IL-6 is the major mediator of the hepatic acute phase response and 
stimulates the hepatic secretion of the acute phase reactants C-reactive protein 
(promotes endothelial dysfunction such as secretion of vascular adhesion molecules 
and selectins and reduces nitric oxide and prostacyclin (PGI2)), serum amyloid A 
(reduces HDL), and fibrinogen (promotes coagulation).16,49,131,194,226,237,251,252  Locally, 
IL-6 induces the expression of vascular adhesion molecules (ie, vascular cell adhesion 
molecule-1 (VACM-1), intercellular adhesion molecule-1 (ICAM-1)) and selectins, 
the reduction of nitric oxide secretion and PGI2, and the expression of monocyte 
recruitment factors and macrophage colony stimulating factors, all of which result in 
the process of inflammation, coagulation, and tissue healing.82,135,162,239,250,252  It also 
inhibits adipose lipoprotein lipase, which is responsible for the breakdown of TG in 
TG-rich lipoproteins, and stimulates lipolysis, increases in FFA levels, and increased 
secretion of TG by the liver, all of which can lead to increased TG, LDL-C, and FFA 
in the blood and reduced HDL-C.66-68,143,252  Thus, IL-6 is designed to promote 
survival when functioning appropriately.27,68  However, when IL-6 levels become 
dysregulated and chronically elevated, these metabolic alterations may also become 
chronic and deleterious to survival.47,54,250,252  In particular, with a potential role in 
mediating some of the pro-atherogenic changes in lipoproteins and lipid metabolism, 
either directly or indirectly through other factors which it stimulates, chronically 
elevated IL-6 may play a role in determining pro-atherogenic lipid profiles.  With 
gene sequence variation being one possible mechanism for inducing elevated IL-6 
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levels, the potentially functional –174G/C promoter polymorphism may be associated 
with lipid profiles.
In Paleolithic times, individuals who exhibited a strong response to infection, 
inflammation, and/or starvation, were conferred a survival advantage.47,131,144  Life 
expectancy was short, life was characterized by physical activity and intermittent 
feedings, and infection and injury were common.47,131,144  Individuals possessing 
genetic variation conferring them “high responder status” would survive and carry 
that variation forward.47,131,144  Thus, humans evolved during a hunter – gatherer 
lifestyle in which they face severe environmental threats, while they now live in a 
time of abundant food and physically inactive lifestyles.47,144  This “maladaptation” of 
lifestyle to a once advantageous genome may be contributing to the spread of many 
poor health conditions.47,144  In light of the known effects of inflammation on lipids 
and lipid metabolism, a genetic predisposition for mounting a greater defense against 
infection and injury (greater inflammatory response) might result in some individuals 
exhibiting a more atherogenic lipoprotein lipid profile as a result of possessing a 
“high responder genotype”.47,105,106,144  With IL-6 being the major regulator of the 
inflammatory response, IL6 genotype may play a role in determining who is 
“advantaged” or “disadvantaged” in terms of plasma lipoprotein lipid levels.   
IL6 Gene 
IL6 is a single copy gene located on the short arm of chromosome 7 (7p21) 
and is comprised of 5 exons and 4 introns.53,231,232  Gene transcription is tightly 
regulated by the NFIL6, NFΚB, Fos/Jun, CRBP, and glucocorticoid receptor 
transcription factors which have binding sites in the –180 to –123 base pair region of 
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the promoter.232  In HeLa cells, this region has been shown to be crucial for virus, 
second messenger, and cytokine induction of transcription with promoter activation 
occurring upon the synergistic action of the NFIL6 (-158 to –145 base pair) and 
NFΚB (-73 to –64 base pair) transcription factors.232  Repression of IL6 expression 
by steroid hormones (estrogen and glucocorticoids) occurs by binding of the hormone 
receptor ligand complexes directly to the transcription factors which prevents their 
binding to the IL6 DNA.232  Thus, the coordinated action of many factors, binding at 
distinct promoter sites, regulates IL6 transcription.232
Several allelic variants have been identified in the 5’ flanking region that may 
influence IL6 transcription.23,51-53,57,98,146,225,232,242  These polymorphisms include the –
597G/A, -572 G/C, -174G/C, and -373AnTn polymorphisms.
23,51-53,57,98,146,225,232,242
However, with previous work supporting strong allelic associations among these 5’ 
flanking region polymorphisms and giving estimates for 94% of the haplotype 
combinations, the literature suggests that the –174G/C promoter polymorphism can 
serve as a marker for the most frequent haplotypes (see Methods on haplotypes).23,51-
53,57,98,146,225,232,236,242  Additionally, studies have shown that the -174G/C 
polymorphism has plausible biological significance in terms of influencing IL6 gene 
transcription and expression and consequently circulating IL6 levels.51-53,232,241
Positioned close to the glucocorticoid receptor binding site, the C allele of this 
polymorphism creates a novel binding site for the NF-1 transcription factor, a 
structurally related family of transcription factors active in many cell types, which 
could repress expression.53  Supporting this, Fishman et al used 5’ region constructs 
and showed that the IL-6 –174 C allele was associated with lower basal and 
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stimulated expression than the G allele in HeLa cells.53  Additional studies have also 
provided support for a potential functional role for the IL6 –174 G/C polymorphism 
in influencing IL6 gene transcription and thus regulation of IL-6 levels, as well as 
suggesting that the C allele results in decreased promoter activity and thus lower 
circulating levels of IL-6.51-53,232,241  However, while evidence supports the 
investigation of the hypothesis that the G allele is associated with higher IL-6 levels 
and potentially detrimental health phenotypes, other investigations using constructs of 
the 5’ flanking region have found evidence of an opposite effect.23,25,96  For example, 
Jones et al.96 found the C allele associated with higher IL-6 levels in a study of 
patients with aneurismal disease.  Burzotta et al.25 also found higher IL-6 levels 
associated with the C allele.  The inconsistency of findings among the in vitro studies 
may be due to the use of different cell lines and culture conditions, use of basal state 
or stimulated cells, nature of the stimulation if used, and presence of other regulatory 
elements in sequences that may induce or repress expression.23  Findings in in vivo 
studies may differ due to differing sample populations.  Thus, while no concrete 
conclusions can be drawn, these studies support further research into the potential 
effect of the IL6 promoter polymorphisms on gene transcription and expression and 
ultimately on circulating IL-6 levels and their association with health phenotypes.
IL-6 Protein Structure, Secretion, and Function
As the final IL6 gene product, IL-6 is an 184 amino acid inflammatory cytokine that 
has a very short biphasic half-life (initial 3 minute and then second 55 minute 
clearance), marked diurnal variability (low in the morning and high at bedtime), and 
large within and between individual variation (30% and 44%, 
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respectively).12,26,30,33,132  It is secreted from multiple cell types, including monocytes, 
macrophages, lymphocytes, fibroblasts, mast cells, astrocytes, microglia, osteoblasts, 
intestinal epithelial cells, endothelial cells, vascular smooth muscle cells and 
adipocytes, as well as contracting skeletal muscle.87,139,139,162,171,172,223,231,252  IL-6 is a 
unique, pleiotropic cytokine in that it has autocrine, paracrine, and endocrine 
functions.80,81,83,139,162,252  It exerts its wide range of actions by binding first to a low-
affinity membrane bound receptor (IL6-R or gp80) that is not a signal 
transducer.80,81,87,252  This IL-6 receptor complex then binds to the high affinity gp130 
which is a signal transducer and, once the IL-6-gp80 complex binds, begins the 
signaling cascade and produces action.80,81,87,252  The IL-6-R is active in both 
membrane and soluble forms which allows cells that do not contain the membrane 
bound form of the gp80 receptor to be targets of IL-6 by binding the IL-6 – soluble 
receptor complex and producing action through gp130.252  Its normal physiological 
functions include roles in neural development, immunity and inflammation, and 
reproduction.80,81,87,139,162,252  However, research has shown that a multitude of factors, 
including the acute phase response mediated release of IL-6, aging, obesity, and 
genetic variation, may result in dysregulation and elevation of circulating IL-6 levels, 
potentially leading to many pathophysiologic 
outcomes.15,23,44,46,50,53,92,94,112,113,243,250,252  Thus, while IL-6 is required for many 
normal physiological functions, its positive, healing role may turn pathological by 
nature of its widespread and redundant actions, health outcomes (including conditions 
such as a chronic inflammatory state, insulin resistance, hypertension, endothelial 
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dysfunction, and dyslipidemia), and potential role in the development of 
atherosclerosis.15,23,44,46,50,53,54,92,94,112,113,162,243,250,252
IL6 –174G/C Promoter Polymorphism, IL-6 Levels, and Health Phenotypes
As discussed, the IL6 –174G/C promoter polymorphism has been shown to 
have biological significance in terms of IL-6 levels and various outcome phenotypes, 
including plasma lipid levels.15,23,44,46,50,53,92,94,112,113,243,250,252  For example, 
Fernandez-Real et al.44,46, Fishman et al.53, and Kubaszec et al.113 found an 
association between the C allele and decreased levels of circulating IL-6.  In contrast, 
Brull et al.23 found an association between the C allele and increased levels of IL-6.  
In terms of health outcomes, Fernandez-Real et al.46 found an association between 
carriers of the G allele and lipid abnormalities (increased TG, VLDL-TG, and apo B 
and decreased HDL2-C), and, in a second study, found an association between the C 
allele and increased insulin sensitivity.  However, Kubaszek et al.113 found an 
association between the C allele and decreased insulin sensitivity.  Humphries et al.92
found that in healthy men levels of the IL-6 surrogate C-reactive protein (CRP) were 
higher, though not significantly different, in C allele carriers compared to those with 
the GG genotype and that the C allele was associated with significantly higher 
systolic blood pressure (SBP) than in the G allele homozygotes.  Berthier et al.15
found an association between the polymorphism and indices of obesity such that the –
174G allele was more commonly observed in lean subjects, and Brull et al.23 found an 
association between the CC genotype and endothelial function in which subjects with 
the CC genotype showed a trend toward greater flow mediated dilatation.  These 
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studies show that associations have been found between the –174G/C polymorphism 
and levels of IL-6 and various health outcomes, but the results are inconsistent with 
respect to the deleterious allele.  Thus, based on the known effect of inflammation in 
inducing pro-atherogenic changes in lipoproteins and lipid metabolism, the 
association of IL-6 with many poor health phenotypes, and the findings associating 
IL-6 levels with increased TG and VLDL and lower HDL-C, the further investigation 
of the potential association between IL6 genotype and plasma lipoprotein lipid levels 
is warranted. 
Exercise Training and Plasma Lipoprotein Lipid Response
Plasma lipoprotein lipid levels are an important independent risk factor for 
CV disease that can be modified through exercise training.21,35,85,109,114-117,141,165,166,195
For example, Durstine et al.35 summarized current cross-sectional and longitudinal 
studies and established that 15-20 miles of brisk walking or jogging per week 
(expenditure of 1200-2200 kcals per week) was associated with increases in HDL-C 
of 2 to 8 mg/dL.  Kraus et al.109 recently found that a relatively high amount of 
regular exercise significantly improved overall lipoprotein profiles, even without 
clinically significant weight loss.  Leon et al.114 also found that 20 weeks of 
endurance exercise training significantly increased HDL-C levels on average by 1.4 
mg/dL.  However, the response of plasma lipoprotein lipids to even standardized 
exercise training is highly variable among individuals.35,64,109,114,116,246  For example, 
while Williams et al.246 found average increases in HDL-C of 4.2 mg/dL in 46 men 
with a one year exercise training program, they also reported that individual changes 
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in HDL-C ranged from a 10 mg/dL decrease to a 20 mg/dL increase in HDL-C.  
Strong evidence suggests that this variability in plasma lipid response to exercise 
training may be due to genetic factors.8,90,91,114,116,181  For example, Rice et al.181
recently studied 115 African American and 99 white families in a 20 week exercise 
training intervention and found that heritable factors accounted for 25-38% of the 
variance in lipid response to exercise training.  For change in HDL2-C in whites, they 
found heritability in response to exercise training as high as 60%.  In another study, 
Leon et al.114 found that genetic contributors accounted for 26-29% of the variance in 
HDL-C changes with training in 675 sedentary sedentary, healthy, white and African 
American men and women aged 17-65 years of age. Additionally, a number of recent 
studies have begun to investigate the potential associations between exercise training-
induced changes in plasma lipoprotein lipids and common polymorphic variations at 
specific genetic loci.14,17,70-73,148,149,217,228,248,249,249  For example, in preliminary data 
from the Gene Exercise Research Study, endothelial lipase (LIPG) genotype had a 
significant effect on baseline lipoprotein lipid levels and also showed significant 
associations with changes with exercise training.74 Thus, this evidence suggests that 
plasma lipoprotein lipid levels and their response to exercise training may be 
regulated by the interaction of lipid metabolism-related genes, their variants, and 
environmental factors.14,17,20,70-73,148,149,174,181,207,209,217,228,248,249,249
Exercise Training and IL-6 
Exercise has been shown to result in increased secretion of IL-6 from both 
skeletal muscle and adipose tissue.40,88,89,103,104,168-172,210,219,223,224,238 For example, IL-
55
6 levels have been shown to increase 100-fold following a marathon.43,172 However, 
neither the mechanisms resulting in the increased secretion nor the implications of the 
increased secretion are fully understood.40,43,88,89,168-172,224,238  Furthermore, the 
influence of the type, intensity, and duration of exercise, while known to increase 
secretion, is not fully understood.  Additionally, the role of genetic variation in 
influencing the response to exercise has not been studied, nor have the effects of a 
regular prolonged exercise-training program been studied in healthy older adults.  
However, researchers have begun to investigate this area and to formulate hypotheses 
regarding exercise, IL-6, and the role of excess secretion and the mediation of 
exercise-induced metabolic changes.40,43,88,89,168-172,224,238
With acute exercise, IL-6 secretion increases in both skeletal muscle and 
adipose tissue.40,43,88,89,168-172,224,238  However, the mechanism behind and action of the 
increased IL-6 differs between the two tissues.  In skeletal muscle, the mechanism for 
increased secretion appears to be the muscle contraction itself and a state of low 
muscle glycogen.168-172  The resulting increase in IL-6 produces local action on the 
skeletal muscle, plus endocrine action as the IL-6 moves through the circulation and 
acts on the liver, adipose tissue, and arterial walls.170  In the liver, the IL-6 stimulates 
glycogenolysis, resulting in the release of glucose that can be used by working 
muscles.170  In adipose tissue, the IL-6 inhibits lipoprotein lipase and stimulates 
lipolysis, resulting in the release of free fatty acids.129,169,171,172  In the artery, the IL-6 
is thought to inhibit the TNF-alpha induced inflammatory effects of insulin resistance 
and atherogenesis (an interesting finding as IL-6 is thought to play its own role in the 
development of such inflammatory response conditions).168-172  In adipose tissue, 
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circulating IL-6 from the contracting muscle acts to stimulate lipolysis while, after 
exercise, sympathetic nervous system stimulation is thought to result in increased IL-
6 secretion with a local effect of increased lipolysis and FFA release.129  Thus, these 
proposed mechanisms suggest that IL-6 may play a role in mediating exercise-
induced metabolic changes.  Current research as summarized by Pedersen et al.168-172
suggests that IL-6 may serve to maintain glucose availability to working muscles 
during exercise, as well as mediate the mobilization of free fatty acids.  This work 
suggests that IL-6 is an additional factor involved in the maintenance of glucose 
levels during exercise.168-172
Thus, in summary, acute exercise has been shown to augment IL6 
transcription rates, mRNA, and release.168,219,220,223  The effect of exercise on changes 
in IL6 gene expression and IL-6 release is influenced by the mode, intensity and 
duration of the exercise, as well as muscular glycogen status.154,168,169,171  The primary 
source of the increase in IL-6 with exercise is thought to be the contracting skeletal 
muscle with the release stimulated by the muscle contraction itself, low intramuscular 
glycogen levels, or changes in energy turnover.40;43,88,89,103,104,168-172,224,238  Other 
organs, including adipose tissue, also release IL-6 during exercise.97,219,223,224  Thus, 
acting as an energy sensor and signaling molecule between the contracting muscle 
and other organs, the IL-6 protein appears to play a role in energy regulation during 
exercise as it functions to maintain glucose availability and mediate the mobilization 
of free fatty acids.224
In terms of exercise training, few data exist on the IL-6 response in healthy 
older adults.  However, some evidence suggests that endurance exercise training may 
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attenuate the IL-6 response to exercise.3,13,59,177,235  Additionally, we know of no 
investigations looking at the interactive effects of endurance exercise training and IL6 
gentoype on IL-6 levels and subsequent effects on plasma lipoprotein-lipids in 
healthy older adults.  
Exercise Training, IL-6, And Plasma Lipoprotein Lipid Response 
While the effect of exercise training is unclear but potentially positive for IL-6 
and known to be favorable for plasma lipoprotein-lipids, the interactive effect of IL6 
genetic variation and endurance exercise training has not been investigated.  
Speculatively, exercise training may have a beneficial effect on inflammatory 
pathways by improving endothelial function, increasing insulin sensitivity and 
heightening the possible anti-inflammatory effects of insulin, and reducing CRP 
levels.224,235  Whether or not these potential benefits are mediated through or reflect 
alterations in IL-6 will require direct functional investigation in future studies.  
However, with much evidence supporting positive changes in plasma lipoprotein 
lipids with exercise training and some evidence supporting the attenuation of exercise 
training on IL-6 levels, it is plausible that these genetic and environmental factors 
may interact in a positive manner to improve lipid profiles.  To date, no research has 
been conducted on this topic, or, even more simply, solely on the interaction of 
exercise training and IL6 genotype on IL-6 levels.  Consequently, in light of the 
growing public health crisis related to the spread of CV disease and the potential 
primary role of IL-6 in the development and progression of that disease, the 
investigation of the interaction between exercise training, IL6 genetic variation, and 
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the impact on plasma lipoprotein lipid response to training is of great interest and 
importance.
CRP As A Surrogate Marker For IL-6 Levels
In 2002, the American Heart Association (AHA) and the Centers for Disease 
Control (CDC) convened a workshop to formulate a consensus regarding the use of 
assays of markers of inflammation in clinical practice.  The result was an evidence-
based scientific paper presenting the major findings and conclusions of the 
workshop.166  The paper presents evidence for inflammation as a mechanism in 
atherosclerosis, provides support for the association of inflammatory markers with 
CV disease, and supports the use of CRP as the inflammatory marker of choice.  
While a number of studies have investigated the potential association between the 
IL-6 –174G/C polymorphism and IL-6 levels, the results have varied 
widely.23,46,53,96,180,241  However, the discrepancies in results may be due to random 
error in the small sample sizes used in these studies that may limit intra-individual 
replicability of IL-6 measures, the lack of timed blood sampling in light of the 
marked diurnal variability of plasma IL-6, and differences in sample population 
(healthy v. existing CV disease).99,215,216,240  These studies highlight the difficulty in 
using direct measures of IL-6 due to its diurnal variability and need for precise, 
consistent collection procedures.  Thus, as IL-6 is the major regulator of the acute 
phase response and the expression of the CRP gene, and CRP is stable and highly 
reproducible, studies have begun to investigate the association between IL6 gene 
variants, and specifically the –174G/C polymorphism, and plasma CRP 
levels.23,51,96,102,130,132,145,235,241  While the first few studies found no association, which 
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may be due to limited sensitivity in the CRP assay and the use of subjects with 
existing CV disease, Vickers et al.160,241 recently found an association between the –
174G/C polymorphism and plasma CRP levels using a family model and determined 
that baseline plasma CRP level is highly heritable (0.39) which supported the findings 
of Pankow et al (CRP heritability of 0.35-0.4).  Vickers et al.241 concluded that their 
results strongly justified the use of typing of the IL-6 –174G/C polymorphism 
together with measures of plasma CRP.  Ferrari et al.51 also found an association 
between the –174G/C polymorphism and CRP levels.  Additionally, Bataille et al.12
conducted experiments in which they found that human CRP production in vivo was 
dependent on IL6 production, thus concluding that CRP levels are a direct indicator 
of IL-6 levels in humans.  Thus, at the present time, the use of CRP as a surrogate 
marker for IL-6 is supported by the literature and is currently the most meaningful, 
viable method of assessing IL-6 response among the subjects in this study.  This will 
provide an opportunity for replication of the approach using CRP as a measure of IL-
6 and will set the stage for future research directly measuring IL-6.  
The subjects for the proposed study are comprised of individuals who completed 
the study over the past five years, as well as those who are currently finishing.  Thus, 
the use of samples from previous cohorts for measuring IL-6 levels will not meet 
rigorous standardization procedures for sample collection, processing, and analysis.  
For accurate comparison, samples should be collected at a consistent time and be 
processed and stored according to assay procedures.  Additionally, samples should be 
analyzed within a year to two years, the same kit should be used to analyze baseline 
and final samples from the same subject, and repeated freeze-thaw cycles of samples 
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should be avoided.  However, unlike IL-6, CRP is highly stable and measurable over 
time and is accepted as a surrogate marker for IL-6.  
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APPENDIX A – Limitations of the Study
Limitations
1. Subjects self-reported many factors related to health and lifestyle such as physical 
activity habits, dietary habits, medication regimens, and medical conditions. It is 
possible that inaccurate self-reports may adversely affect the results of the study.
2. While each subject does serve as their own control, there is no separate control 
group in this study.  Thus, it is possible that seasonal variation or subject aging 
may influence the results.  
3. The NMR lipid analyses were conducted on single plasma samples, therefore the 
results could be affected by the known daily variation in plasma lipoprotein lipid 
levels.  
4. Plasma IL-6 levels were not measured directly in this study, and CRP levels were 
used as a surrogate measure.  The use of CRP measures in place of direct 
measures of IL-6 is based on the following:
1) the AHA/CDC Scientific Statement recommendations regarding 
markers of inflammation and cardiovascular disease and the 
application to clinical and public health practice166;
2) the precedent found in the literature for the use of CRP as a measure 
of IL-6 and the nature of the IL-6 molecule12,145; and
3) the difficulties in assuring consistency in sample collection, 
processing, and analysis procedures for subjects having already 
completed the GERS study.  
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Delimitations
1. Approximately 65 subjects recruited from the University of Maryland – College 
Park campus and surrounding areas were evaluated for plasma lipoprotein-lipid 
levels and response to endurance exercise training.
2. Due to the low frequency of the less common C allele in African Americans 
(0.08) as compared to Caucasians (0.37-0.44) and the relatively small projected 
sample size and genotype/allele frequency for African Americans (N=30; GG=24, 
GC=4, CC=1; G=55, C=5), the analyses included only Caucasians as the 
inclusion of African Americans would result in merely adding to the common 
allele pool without contributing to analysis of the rare allele.28,78,94,98,150
3. Subjects were healthy males and females, 50-75 years of age, sedentary as 
determined by questionnaire and personal interview, non-diabetic as determined 
from a 2-hour glucose tolerance test, free from cardiovascular disease as 
determined by a graded exercise test (GXT), and not taking medications known to 
affect lipid metabolism.  Therefore, the results most specifically apply to 
populations with similar characteristics.
4. All female subjects enrolled in the study were at least 2 years postmenopausal and 
remained either on or not on hormone replacement therapy (HRT) throughout the 
duration of the study.  Since HRT may affect lipid metabolism and IL-6 action, 
female subjects maintained their current HRT status throughout the study.  While 
statistical control can be applied, it is possible that HRT status may affect 
genotype and/or training effects on the outcomes.
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5. Participants were asked to follow the American Heart Association’s Dietary 
Guidelines for the General Population with <30% of calories from fat and 
cholesterol intake of <300 mg/d for the duration of the study.111
6. In addition to the –174G/C promoter polymorphism, three additional 
polymorphisms that have been identified in the 5’ flanking region of the IL6 gene 
were not assessed in this study (–597G/A, -572 G/C, -373AnTn).
23,51-
53,57,98,146,225,232,236,242  However, previous work supports strong allelic associations 
among these 5’ flanking region polymorphisms, gives estimates for 94% of the 
haplotypes at these loci, and suggests that the –174G/C promoter polymorphism 
serves as a marker for the most frequent haplotypes.23,51-53,57,98,146,225,232,236,242
Therefore, knowing the –174G/C genotype allows for the estimation of 94% of 
the haplotype combinations for these three loci (GGG 54%; AGC 40%), and, with 
only 65 subjects, typing of additional loci would only identify 4 additional 
subjects beyond the 61 identified by the –174G/C site.  Thus, as this study 
consists of only a modest sample size and the genotyping and analysis of these 
additional SNPs would provide no additional information above that found from 
analyzing the –174 G/C site alone, the present investigation focuses only on the –
174G/C locus.  
7. Lipids were analyzed using conventional methods at the Baltimore Veterans 
Administration Medical Center (VAMC) using a CDC standardized Hitachi 717 
autoanalyzer 4,205, as well as by using nuclear magnetic resonance (NMR) 
techniques (LipoScience, Raleigh, NC) previously standardized and validated 
against conventional methods of separation and analysis.157-159,190,212  Body 
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composition was analyzed at the Baltimore VAMC using dual-energy x-ray 
absorptiometry (DPX-L; Lunar Corp, Madison, WI).142
8. All exercise training sessions were conducted at the Wellness Research 
Laboratory at the University of Maryland – College Park. 
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APPENDIX B – Definition of Terms
Cytokine. Secreted by many cells types, these low-molecular weight, 
hormone-like proteins regulate immune response intensity and duration, as well as 
mediate cell-to-cell communication.
Interleukin. A group of multifunctional cytokines synthesized by 
lymphocytes, monocytes, macrophages, and certain other cells.  They have a known 
amino acid structure.
Lipoprotein Nuclear Magnetic Spectroscopy Measured Subfractions.
Traditionally, lipoprotein analysis has recognized VLDL, LDL, and HDL 
subclasses of increasing density and decreasing size (VLDL – large, intermediate, 
small; LDL – (IDL1 and 2), I, II a, II b, III a, III b, IV a, IV b; HDL – HDL2b, 
HDL2a, HDL3a, HDL3b, HDL3c).  Nuclear magnetic resonance spectroscopy 
analysis also distinguishes between these subfractions, but designates them as 
follows:  VLDL - V6, V5, V4, V3, V2, V1; LDL – IDL, L3, L2, L1; HDL – H5, H4, 
H3, H2, H1; respectively.  The approximate range in nanometers for these particles is 
as follows:
VLDL (V6-V1) = 150±70, 70±10, 50±10, 38±3, 33±2, 29±2
LDL (IDL, L3-L1) = 25±2, 22±0.7, 20.5±0.7, 19±0.7
HDL (H5-H1) = 11.5±1.5, 9.4±0.6, 8.5±0.3, 8.0±0.2, 7.5±0.2
The NMR analysis takes advantage of the fact that different sizes of lipoprotein 
particles have specific proton NMR spectroscopic signatures.149,155-159,212
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Sedentary.  Sedentary individuals are those who are not physically active.  In 
the proposed study, sedentary is defined as performing aerobic exercise for no more 
than 20 minutes two or more times a week over the past 6 months.
Triglyceride. Triglycerides are a type of fat in the blood that are comprised of 
three fatty acid molecules esterified to a glycerol molecule.
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APPENDIX C – Human Subjects Approval and Consent Form
Title:  Interleukin-6 (IL6) Genotype, Plasma Lipoprotein Lipids, and Their Response 
To Exercise Training
Applicant:  Amy Halverstadt
Advisor:  Dr. James Hagberg
1.  Abstract
A small body of literature suggests an association between the interleukin-6 
(IL6) G-174C gene polymorphism and plasma lipoprotein-lipid levels such that the G 
allele may be associated with a more pro-atherogenic lipid profile than the C allele.  
However, no research exists regarding the potential IL6 gene x physical activity 
interaction.  Thus, the purpose of this proposed study is to assess the association 
between the IL6 G-174C gene polymorphism, plasma lipid profiles, and their 
response to exercise training.  It will be of particular interest to determine whether 
individuals carrying the G allele demonstrate a pro-atherogenic lipid profile versus 
non-carriers and to compare their lipid changes with exercise training.  In a more 
general sense, the proposed study will contribute to understanding the great inter-
individual variability in plasma lipoprotein lipid levels and their response to exercise 
training and may aid in the design of individualized treatment and prevention 
strategies targeted at improving plasma lipid profiles.  The study will employ a 
standardized exercise training intervention in healthy 50-75 year olds, conduct 
baseline and final testing that includes NMR measurement of plasma lipoprotein 
lipids, genotype subjects at the identified IL6 gene locus, and assess the potential 
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association of the IL6 –174G/C polymorphism with plasma lipoprotein lipid levels 
and their responses to exercise training.
2.   Subject Selection
a) Who will be the subjects?  How and from where will they be obtained?                      
The subjects in this study will have taken part in the Gene Exercise Research 
Study “APO E genotype and HDL changes with exercise training” study (IRB 
approval number 00494) at the University of Maryland.  These individuals are men 
and women from the population in the vicinity of the University of Maryland 
(Washington, D.C. metropolitan area) who responded to media advertisements 
(newspaper and magazine advertisements, radio public service announcements, flyers 
mailed to citizens in the metropolitan area). 
b) Are the subjects being selected for any specific characteristics?
Subjects in the Gene Exercise Research Study are screened via telephone and 
with the use of laboratory assessments to meet eligibility requirements.  Subjects 
must be sedentary (aerobic exercise ≤ 2 times/week, < 20 minutes/session, sedentary 
job), 50-75 years of age, nondiabetic, normotensive or blood pressure controlled with 
non-lipid and non-glucose altering medication, no history of chronic obstructive lung 
disease, a body mass index (BMI) < 37 kg/m
2
, and no physical or orthopedic 
conditions that would preclude vigorous exercise.  In addition, women must be 
postmenopausal (absence of menses for ≥ 2 years) and agree to maintain their 
hormone replacement status during the study, either receiving or not receiving 
hormone replacement therapy.  
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c) State why the selection is made on the basis given in (2).
These criteria are necessary to ensure subjects have no known conditions 
limiting participation in any of the Gene Exercise Research Study testing procedures 
and to help control for extraneous variables, which could affect plasma lipoprotein 
lipid levels.  In addition, individuals aged 50-75 were chosen as the subject 
population since they represent a high risk group for cardiovascular disease (CVD) 
and preventive measures could make an impact on their health.   
3.  Procedures  
Data from subjects in the Gene Exercise Research Study will be used to 
separate the subjects into groups based on their IL6 –174G/C genotypes.  Then, the 
subjects’ plasma lipoprotein lipid levels and responses to exercise training will be 
compared among genotype groups.  Possible confounding factors, including gender, 
body composition, and age, will be used as covariates in the statistical analyses to 
control for their effects.     
Orientation Visit: Telephone screened subjects interested in participating in 
the Gene Exercise Research Study come to the laboratory and have their medical 
history forms reviewed to determine if they meet inclusion criteria.  They then have 
the Gene Exercise Research Study explained to them.  Any questions are answered 
and those interested in participating provide their written informed consent.  The 
subjects are then scheduled for Screening Visit 1.  
Screening Visit 1:  Following an overnight fast, subjects have a blood sample 
drawn for standard blood chemistry tests.  Subjects are excluded if they have plasma 
triglycerides > 400 mg/dL, a hematocrit < 35, evidence of renal or liver disease, or 
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fasting glucose > 126 mg/dL.  The fasting blood sample is immediately evaluated 
using a One-Touch Glucometer.  If the fasting blood glucose is > 126 mg/dL, the 
subject does not continue with the remaining Screening Visit 1 procedures.  If clinical 
laboratory analysis confirms a fasting glucose > 126 mg/dL, the subject is excluded 
from the study.  If the laboratory analysis does not confirm a fasting glucose > 126 
mg/dL, then the subject is rescheduled for a second Screening Visit 1 appointment.  
Subjects also undergo a 2-hour OGTT, where they drink a 75-gram glucose 
solution and have a blood sample drawn 2 hours later.  If the blood glucose level 2 
hours after the glucose challenge is > 200 mg/dL, the subject is excluded from the 
study.  To be included in the study, subjects must also have at least one National 
Cholesterol Education Program lipid abnormality (cholesterol > 200 mg/dL, HDL < 
35 mg/dL, triglyceride > 200 but < 400 mg/dL, or LDL > 130 mg/dL).  Height and 
weight are also measured to calculate BMI to ensure subjects meet the BMI < 37 
kg/m2 criteria.  
During Screening Visit 1, DNA is also extracted from the fasting blood 
sample for genotyping.  DNA is isolated from peripheral monocytes and genotyped in 
the University of Pittsburgh Laboratory of Dr. Robert Ferrell.  Genotyping of the IL6 
-174G/C gene involves the use of DNA that was frozen for future studies associated 
with the goals of the Gene Exercise Research Study.   
Screening Visit 2: Those individuals continuing to qualify for the study 
undergo a second screening visit consisting of a general physical examination and a 
maximal graded treadmill exercise test, using the Bruce protocol, to screen for CVD.  
Blood pressure, electrocardiogram (ECG), and heart rate are recorded before the test, 
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at the end of every stage in the test, and every other minute for 6 minutes during 
active recovery from the exercise test.  A subject is excluded from the study if his or 
her blood pressure response to exercise is abnormal, the test is terminated due to 
cardiovascular symptoms, or the subject has ST segment depression greater than 2 
mV.
Dietary Stabilization: After screening into the study, subjects attend dietary 
lectures on the principles of an American Heart Association low-fat diet, twice a 
week for 6 weeks.  Subjects maintain the diet throughout the duration of the study, 
with periodic dietary recalls and food frequency checks to ensure adherence.  In 
addition, subjects are instructed to maintain caloric intake throughout the study, since 
weight loss can influence many health and fitness variables.  Subjects are weighed 
weekly and those losing more weight than expected are counseled to increase their 
caloric intake.
Baseline Testing: After dietary stabilization, the subjects undergo baseline 
testing, which includes body composition scans, a 3-hour OGTT, and plasma 
lipoprotein lipid measures.  The 3-hour OGTT takes place following a 12-hour 
overnight fast.  A catheter is placed in an antecubital vein, and blood sampling occurs 
before and every 30 minutes after the ingestion of a 75-gram glucose solution, for 3 
hours.  Body composition is measured via dual energy x-ray absorptiometry at the 
Baltimore VA Medical Center, using standard procedures. 
To analyze plasma lipoprotein lipid levels, subjects have fasting samples 
drawn on two separate occasions, with the values averaged.  If these measures differ 
by > 10%, a third separate measurement is included in the average.  Plasma TG and
72
cholesterol levels are analyzed using a CDC standardized Hitachi 717 autoanalyzer.  
HDL-C is measured after precipitation with dextran sulfate, and LDL-C is calculated 
using the Friedewald equation.  HDL2-C and HDL3-C are separated using a second 
high-molecular weight dextran sulfate precipitation with HDL3-C measured and 
HDL2-C calculated.  Nuclear magnetic resonance (NMR) techniques (LipoScience, 
Raleigh, NC) are used to determine plasma lipoprotein lipids, using techniques 
previously standardized and validated against conventional methods of separation and 
analysis.  NMR measures are made on a single blood sample that is frozen at –80° C 
and analyzed at the same time as final test samples.
  This sub-study of the Gene Exercise Research Study will be conducted in the 
Department of Kinesiology at the University of Maryland, College Park.  Gene 
Exercise Research Study procedures take place cooperatively at the University of 
Pittsburgh, the University of Maryland at Baltimore, and the University of Maryland, 
College Park.    
4.  Risks and Benefits
There are potential risks associated with participation in the Gene Exercise 
Research Study and, consequently, this sub-study.  There are risks involved with 
graded treadmill exercise testing of approximately 1 nonfatal event in 10,000 
maximal treadmill tests and 1 fatal cardiac event in 70,000 maximal treadmill tests.  
To minimize these risks, American Heart Association CPR and AED certified 
personnel administer the tests.  In addition, a physician experienced in arrhythmia 
detection and exercise testing will be present at every treadmill test.  Subjects will be 
screened with a physical exam and resting ECGs in the supine, seated, and standing 
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positions prior to starting the graded exercise test.  An emergency cart with 
medications and an AED will be present at all tests.  
There is a potential risk of bruising and infection with the blood drawing 
procedures.  Using aseptic techniques and having trained laboratory technicians draw 
the blood samples will minimize these risks.
There is a risk of malignancies due to x-ray exposure during the body 
composition scans.  Exposing the subject to 0.02 mRem/scan, which is equal to 30 
minutes of natural background radiation exposure, will minimize these risks.
There are no risks associated with the genetic testing since the participants are 
not provided with information regarding their genetic test results.  The laboratories 
that perform the genetic tests are not clinically certified, thus the genetic results 
cannot be used for diagnostic purposes.  
The OGTT involves risks due to blood drawing, the potential for a 
hypoglycemic reaction at the end of the test, and the possibility of an upset stomach 
after ingestion of the glucose solution.  To minimize these risks, the blood drawing 
techniques described above will be employed, subjects will receive juice and a snack 
after the test to prevent a hypoglycemic response, and subjects will be monitored 
closely throughout the test so that a drink and snack can be provided if symptoms of 
hypoglycemia appear.
Each subject in the Gene Exercise Study receives his/her dietary assessments, 
test results (except genetic tests), and interpretations of the results.  As part of the 
Gene Exercise Study, the subjects also receive six months of aerobic exercise 
training.  Overall, the results of this study will help explain if genetic polymorphisms 
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affect the variability in HDL-C, its subfractions, and responses to exercise training in 
50-75 year old men and women.  With the prevalence of cardiovascular disease in 
society today, identifying factors that influence plasma lipoprotein lipid metabolism 
and composition is beneficial to helping understand mechanisms of disease and 
possible treatment strategies.   
5.  Confidentiality
Gene Exercise Research Study subject data is entered into a database with 
access granted only to qualified study personnel.  All blood samples for genetic 
analysis are numbered and sent to the University of Pittsburgh and University of 
Maryland at Baltimore for analysis, so the samples there are unrelated to any specific 
research subjects.  All samples sent to LipoScience in Raleigh, NC for NMR 
measured lipid analyses are also numbered such that the samples are unrelated to any 
specific research subject.  Only the Gene Exercise Research Study Primary 
Investigator and Study Coordinator know the subject names corresponding to the 
coded numbers.  Presentations of study results will not reference subject names and 
all data from subjects will be grouped together for reporting purposes.
6.  Information and Consent Forms
Subject study results (except genetic tests) are provided to the subject in 
written form with explanations attached.   Also, it is indicated that the results are not 
for diagnostic use, as they are not generated from clinically approved laboratories.  A 
subject’s written consent is obtained following an orientation meeting, where the 
study specifications and consent form are explained in detail by the investigators. 
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7.  Conflict of Interest
Investigators do not have a real or potential conflict of interest.
8.  HIPAA Compliance
The researchers working on this project are not employed by the University 
Health Center and thus are not subject to specific HIPAA requirements regarding the 
creation, use, disclosure, or access of protected health information.  Subject personal 
identification information will remain confidential by the methods described in this 
and the original IRB applications.  The attached informed consent details the 
procedures for the handling of confidential information.
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CONSENT TO ACT AS A SUBJECT IN AN EXPERIMENTAL STUDY
Project Title: APO E genotype and HDL Changes with Exercise Training
     I state that I am over 18 years of age and wish to participate in a program of 
research being conducted by Dr. James Hagberg in the Department of Kinesiology, 
University of Maryland.
     The purpose of this study is to determine the role that genetics may play in 
determining how my blood cholesterol levels change with exercise training.
     I already completed a telephone interview that determined that I am not physically 
active, am 50 – 75 years of age, not a diabetic or have controlled diabetes, not taking 
cholesterol-lowering medications, have normal blood pressure or high blood pressure 
controlled on medications not affecting my cholesterol levels, have no evidence of 
lung disease, have an appropriate weight for my height, and have no other medical 
problems that would keep me from exercising vigorously.  Furthermore, if I am a 
woman, I must be postmenopausal, defined as no menstrual cycles for at least the last 
2 years.  I understand that if I am a woman and change my hormone replacement 
therapy regimen during the study, my participation in the study will be terminated.  I 
also understand that if I have a prior history of ulcers or bleeding disorders, I will be 
excluded from one test that is part of this study.  I also understand that I must have 
somewhat abnormal levels of cholesterol to enter the study.
     I understand that I will complete one orientation and two screening visits.  The 
orientation session will present all aspects of the study and my written informed 
consent will be provided after all of my questions have been answered.  For my first 
Screening Visit, I will report to the laboratory in the morning after an overnight fast 
and a blood sample will be drawn for blood chemistries and blood cholesterol levels.  
I understand that I may be excluded from the study if this initial blood sample shows 
elevated levels of glucose in my blood.  I understand that a part of this blood sample 
will be used to obtain my DNA.  A blood sample will also be drawn 2 hours after I 
drink a sugar solution.  I understand that a total of 3 tablespoons of blood will be 
drawn during this visit.  I understand that I will be excluded from the study at this 
point if I have low cholesterol levels, high triglyceride levels, a low red blood cell 
count, evidence of kidney or liver disease, or evidence of diabetes.  I understand that 
if I remain qualified to this point, on my second Screening Visit I will undergo a 
treadmill exercise test to determine if I have heart disease.  A physical examination 
will precede the exercise test.  I will then complete a test on an exercise treadmill 
where the treadmill speed and grade will increase every 3 minutes until I cannot 
continue or symptoms of heart disease develop.  Blood pressure, heart rate, and ECG 
will be recorded before, during, and after the test.  I understand that I will be excluded 
from the study at this point if I have evidence of heart disease.
Page One of Five
Initials________________
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I understand that if I meet all of these requirements to enter the study, I will undergo 
6 – 8 weeks of instruction in the principles of an American Heart Association low-fat 
diet and must follow this diet for the remainder of this study.  After this I will 
undergo Baseline Testing that includes the following tests that will be completed in 5 
testing sessions.  I will have blood drawn on 2 or 3 occasions from a vein in my arm 
in the morning after an overnight fast to measure my cholesterol levels and to assess 
my immune system.  I understand that a maximum of 2 tablespoons of blood will be 
drawn during these visits.  I understand that I will also undergo a second exercise test 
on a treadmill to measure my cardiovascular fitness.  This test will start at 70% of the 
highest heart rate achieved on my first exercise test and the treadmill grade will 
increase by 2% every 2 minutes.  Blood pressure, heart rate, and ECG will be 
monitored before, during, and after the test.  The test will be stopped when I can no 
longer continue.  During this test I will have a nose clip on my nose and I will breathe 
through a mouthpiece so that the air that I breathe out can be analyzed.  I also 
understand that my dietary habits will be measured by having me record for 7 days all 
of the food items that I eat.  I understand that on another morning after an overnight 
fast I will have blood samples drawn before and for 3 hours after I drink a glucose 
solution to assess my risk of developing diabetes; I will also have additional blood 
drawn prior to this test that will be frozen for future studies that relate directly to the 
goals of the present study.  I understand that 5 tablespoons of blood will be drawn 
during this visit.  I understand that on another occasion after an overnight fast, I will 
have blood samples drawn from a line (catheter) in my arm before and for 4 hours 
after drinking approximately 1 – 2 cups of a high-fat liquid meal.  The high-fat meal 
is made of heavy whipping cream with small amounts of chocolate, sugar, and 
powdered milk and tastes similar to a rich chocolate shake.  I understand that 10 
tablespoons of blood will be drawn during this test and will be used to measure how 
my body absorbs and uses fat from a meal and how my blood clotting, and substances 
that affect hunger are affected by a fat meal.  Before and after I drink the high-fat 
meal, I understand that I will breath through a mouthpiece wile my nose is closed-off 
with a nose clip and the air that I breathe out will be collected and used to determine 
how much fat I use for energy while sitting at rest.  I understand that these tests will 
be done at the University of Maryland College Park.
     I understand that in the morning after an overnight fast I will have blood samples 
drawn to assess my cholesterol levels and my blood clotting system.  I will then have 
a substance that temporarily stops blood from clotting injected into my arm vein.  
Blood samples are drawn 10 min later for measurement of chemicals that affect blood 
cholesterol levels.  I understand that if I have a prior history of ulcers or bleeding 
disorders I will not undergo this test.  I understand that I will remain in the laboratory 
for 2 – 3 hours after this test with pressure on the site where blood samples were 
drawn to make sure that all bleeding is stopped.  I understand that 4 tablespoons of 
blood will be drawn during this visit.  I understand that how much fat and muscle I 
have will be measured using x-rays while I lay quietly on a table for 15 to 30 minutes.
I understand that the amount of fat I have around my waist will be measured with a
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CAT scan while I lie quietly on a table.  I also understand that these last 3 tests will 
be done at the VA Medical Center in Baltimore.
     I understand that during this Baseline Testing a total of 21 tablespoons of blood 
will be drawn, which is about two-thirds of the amount of blood given when donating 
blood.   
     I understand that after completing this testing, for 6 months I will complete 3 
exercise sessions each week supervised by study personnel.  I understand that I will 
be instructed on appropriate warmup and stretching exercises to perform prior to each 
exercise training session.  I will be taught to measure my heart rate and to use heart 
rate monitors to control how hard I am exercising.  The first training sessions will 
consist of 20 minutes of light exercise.  The amount of exercise and how hard I 
exercise will increase gradually until I am completing 40 minutes of moderate 
intensity exercise every session.  Exercise modes include walk/jogging, stairstepping, 
and cycle, cross-country ski, and rowing ergometry.  I will be asked to add a 45-60 
minute walk to my exercise program on weekends after the first 10 weeks of the 
exercise program.  I understand that some of the supervised exercise sessions may be 
done outside of the exercise facility, but still under the direct supervision of study 
personnel.  I understand that if I lose more weight than expected from exercise, I will 
be counseled by a dietitian against restricting how much food I eat.  I will also be 
asked to complete food records during the exercise training program and if major 
dietary changes have occurred, I will also be counseled by a dietitian to resume my 
original dietary habits.
     I understand that after completing 6 months of exercise training, I will have 
everything reevaluated that was measured before I began the exercise program.  I 
understand that during this testing a maximum of 21 tablespoons of blood will be 
drawn, which is about two-thirds of the amount of blood given when donating blood.
     I understand that if I qualify for this study that my DNA will be isolated from my 
blood and analyzed at a number of sites for differences in DNA that may affect how 
my cholesterol levels change with exercise training.  I understand that some of my 
DNA will also be frozen for future studies.  However, these studies can only analyze 
my DNA at sites that might affect how my cholesterol levels, glucose and insulin 
levels, bone density, body composition, immunology (disease-fighting), and 
cardiovascular and blood clotting systems change with exercise training.  
     All information collected in this study is confidential, and my name will not be 
identified at any time.  I understand that my DNA (genetic material) will be sent to 
collaborating genetics laboratories that are part of this study and that a sample of my 
DNA will be kept in the University of Maryland Department of Kinesiology 
laboratories.  I understand that my coded blood samples will also be sent to other 
collaborating laboratories to measure compounds in my blood that relate to blood 
cholesterol levels and cardiovascular disease risk.  I understand, however, that all my
blood samples sent to collaborating laboratories will be identified only by a numeric
code.  I understand that only investigators at the University of Maryland College Park
will know whose name is associated with each coded number.  I further understand
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that the list of names and codes will be retained at the University of Maryland 
College Park for up to 25 years.
     I understand the following risks are associated with my participation in this study.  
(1) The risk of maximal exercise testing is approximately 1 nonfatal event in 10, 000 
tests and 1 fatal cardiac event in 70,000 tests.  Risks will be minimized by having the 
test administered by a physician and personnel trained in such tests and emergency 
procedures.  I will be screened with a resting ECG and a physical examination prior 
to this test.  An emergency cart with the necessary drugs and a cardiac defibrillator 
will be present at all testing sessions.  (2) There is minimal risk of bruising and 
infection associated with the blood drawing.  These risks will be minimized by using 
sterile techniques and by having experienced personnel draw all blood samples.  (3) 
The risk if the body composition testing is the exposure to X-rays.  The amount of X-
ray exposure for this test is the same as that occurring during 30 minutes of any 
activity outside in the sun.  (4) The risk associated with the test requiring the injection 
into an arm vein of a substance that temporarily stops blood clotting is bleeding.  This 
risk will be minimized by excluding persons with bleeding disorders, peptic ulcers, or 
other blood disorders from the study.  The risk is further minimized by placing a 
pressure bandage on the intravenous access site after the blood sampling and 
observing the subject for 2-3 hours after the injection.  (5) The risk associated with 
the CAT scan to measure abdominal fat is the exposure to X-rays.  The X-ray 
exposure is less than the maximum radiation dose individuals are permitted to be 
exposed to each year in their occupation.  (6) The risks associated with the blood 
clotting and immune system studies are those related to blood drawing as listed 
above.   (7) The risks associated with the oral glucose tolerance test and the high-fat 
meal test are those associated with blood drawing, the possibility of having low blood 
sugar levels at the end of the test, and the possibility of having an upset stomach, 
primarily a stomach ache, after drinking the glucose and /or high fat meals.  The risk 
of low blood sugar levels at the end of the test will be minimized by providing you 
with a drink and small snack.  (8) The risk of exercise training is the possibility of a 
heart attack or other cardiovascular event.  A large physical activity center reported 
that 1 nonfatal cardiovascular event occurred in 1.7 million walk/jogging miles.  
These risks will be minimized because I will undergo a cardiovascular evaluation 
before beginning exercise training.  Exercise sessions will be supervised by 
experienced personnel trained in emergency procedures.  An emergency cart with the 
necessary drugs and a cardiac defibrillator will be present at all supervised exercise 
training sessions.  Two study personnel will supervise the outside exercise sessions 
done at the University of Maryland, College Park though no emergency equipment 
will be directly available during these sessions.  (9) There are no risks associated with 
the genetic testing because no results of these tests will be given to the participants.  
This has to be the 
case because the genetic results are not from clinically-approved laboratories.
     I understand that this study is not designed to help me personally, but may help the 
investigators to determine who exercise might benefit the most.  I understand that I 
will be provided with my study results and they can be sent to my physician if I 
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request this in writing.  I understand that these results are not to be used for clinical 
diagnostic purposes and that I will not receive the results of my genetic testing.  I 
understand that I am free to ask questions or to withdraw from participation at any 
time without penalty.  I understand that I will be paid $50 for completing Baseline 
Testing after the dietary stabilization period.  I also understand that I will be paid 
another $50 for completing 3 months of exercise training and another $100, for a total 
of $200, for completing 6 months of exercise training and all final testing, if I 
complete at least 90% of my exercise training and testing sessions.  I understand that 
if my participation in the study has to be terminated because I change my hormone 
replacement therapy regimen, I will only be paid for the portion of eth study that I
have already completed, that is, which of the stages above that I have completed.
     In the event of a physical injury resulting from participation in the study, I 
understand that immediate medical attention is available at the Washington Adventist 
Hospital or the Baltimore VA Medical Center.  However, I understand that the 
University of Maryland does not provide any medical or hospitalization coverage for 
participants in this research study nor will the University of Maryland provide any 
compensation for any injury sustained as a result of participation in this research 
except as required by law. 
Principal Investigator: James Hagberg, PhD, Department of Kinesiology, HLHP 
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